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Abstract Exposure to a variety of toxins and/or infec-
tious agents leads to disease, degeneration and death, often
characterised by circumstances in which cells or tissues do
not merely die and cease to function but may be more or
less entirely obliterated. It is then legitimate to ask the
question as to whether, despite the many kinds of agent
involved, there may be at least some unifying mechanisms
of such cell death and destruction. I summarise the evi-
dence that in a great many cases, one underlying mecha-
nism, providing major stresses of this type, entails
continuing and autocatalytic production (based on positive
feedback mechanisms) of hydroxyl radicals via Fenton
chemistry involving poorly liganded iron, leading to cell
death via apoptosis (probably including via pathways
induced by changes in the NF-jB system). While every
pathway is in some sense connected to every other one, I
highlight the literature evidence suggesting that the
degenerative effects of many diseases and toxicological
insults converge on iron dysregulation. This highlights
speciﬁcally the role of iron metabolism, and the detailed
speciation of iron, in chemical and other toxicology, and
has signiﬁcant implications for the use of iron chelating
substances (probably in partnership with appropriate anti-
oxidants) as nutritional or therapeutic agents in inhibiting
both the progression of these mainly degenerative diseases
and the sequelae of both chronic and acute toxin exposure.
The complexity of biochemical networks, especially those
involving autocatalytic behaviour and positive feedbacks,
means that multiple interventions (e.g. of iron chelators
plus antioxidants) are likely to prove most effective. A
variety of systems biology approaches, that I summarise,
can predict both the mechanisms involved in these cell
death pathways and the optimal sites of action for nutri-
tional or pharmacological interventions.
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SIRS Systemic inﬂammatory response
syndrome
TCDD, ‘dioxin’ 2,3,7,8-tetrachlorodibenzo-p-dioxin
TSEs Transmissible spongiform
encephalopathies
2,4-D 2,4-dichlorophenoxyacetic acid
2,4,5-T 2,4,5-trichlorophenoxyacetic acid
Introduction
As a transition metal that can exist in several valencies, and
that can bind up to six ligands, iron is an important compo-
nent of industrial catalysts in the chemical industry (Hagen
2006),especially forredox reactions.Its catalysisofspeciﬁc
reactions requires rather exact architectures at the catalytic
centre, and indeed much of the art and science of catalyst
production involves determining and synthesising them.
Nearly half of all enzymes are metalloproteins (Waldron
et al. 2009), and iron is also of considerable importance in
biology as a component of all kinds of metalloproteins
(Andreini et al. 2008, 2009) from haemoglobin to cyto-
chromes,aswellasinthedirectedevolutionofnovelenzyme
activities (Pordea and Ward 2008; Que and Tolman 2008;
Turner2009).Whenservinginenzymes,theironisnormally
safely liganded, and any reactions catalysed are usually
fairly speciﬁc. However, as is widely recognised, iron can
also have a dark side (Kell 2009a), in that when it is not
properly liganded (Graf et al. 1984), and in the ferrous form,
it can react with hydrogen peroxide (produced by mito-
chondria(e.g.BrennanandKantorow2009;Fatoetal.2008;
Orrenius et al. 2007) or (per)oxidases (Bedard and Krause
2007; Cave et al. 2006) via the Fenton reaction (Goldstein
etal.1993;Kruszewski2003;Toyokuni2002;Wardmanand
Candeias 1996; Winterbourn 1995), leading to the very
reactive and damaging hydroxyl radical (OH
•)
FeðIIÞþH2O2 ! FeðIIIÞþOH  þ OH  ð1Þ
Superoxide (also produced by mitochondria) can react
with ferric iron in the Haber-Weiss reaction (Kehrer 2000)
to produce Fe(II) again, thereby effecting redox cycling of
the iron (Fig. 1):
O  
2 þ FeðIIIÞ!O2 þ FeðIIÞð 2Þ
Ascorbate (vitamin C) can also replace O  
2 for reducing
the Fe(III) to Fe(II) (Hershko and Weatherall 1988), as can
other reducing agents, and indeed too low a redox poise
leads to DNA damage (e.g. Li and Marba ´n 2010; Seifried
et al. 2007).
The hydroxyl radical is exceptionally reactive and dam-
aging to cellular components, and, for instance, can liberate
further Fe(II) from iron-sulphur centres and other iron-con-
taining compounds such as ferritin (Arosio et al. 2009),
thereby driving reaction (1) in an autocatalytic, runaway
kind of reaction. This kind of phenomenon has the potential
to overwhelm any kinds of attempts at repair, and inﬂam-
mation and oxidative stress are the hallmarks of each of the
conditions I summarise. Related reactions include perox-
ynitriteproduction(fromthereactionofNOandsuperoxide)
(Babior2000;Beckman etal.1990;Beckman andKoppenol
1996; Goldstein and Mere ´nyi 2008; Koppenol et al. 1992;
Murphy et al. 1998; Pacher et al. 2007; Pavlovic and
Santaniello2007;PryorandSquadrito1995;Radietal.2001,
2002; Rubbo and O’Donnell 2005; Rubbo et al. 2009; Smith
et al. 1997b; Squadrito and Pryor 1998; Szabo 1996; Szabo ´
et al. 2007; Torreilles et al. 1999; White et al. 1994; Zimmet
and Hare 2006). These can lead to nitrotyrosine (Beckman
1996; Goldstein and Mere ´nyi 2008; Herce-Pagliai et al.
1998) (a reaction catalysed by poorly liganded iron,
Beckman et al. 1992), or nitro-fatty acid (Aslan et al. 2001;
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Fig. 1 The Haber-Weiss and Fenton reactions combine using poorly
liganded iron in a catalytic cycle to produce the very damaging
hydroxyl radical. Poorly liganded iron can also be liberated via the
destruction of haem and other iron-containing substances. Peroxyni-
trite anion (ONOO
-) is produced by the reaction of superoxide and
nitric oxide (NO
•) which when protonated (pH ca 6.5–6.8) decom-
poses to OH
• and NO2
Some small molecules derived 
from macromolecule oxidation
8-OH-2’-deoxyguanosine ￿D N A
￿ Proteins nitrotyrosine, methionine
sulphoxime
￿ Lipids  4-hydroxy-non-2-enal
Fig. 2 Some small molecules that are derived from the oxidative
attack of hydroxyl and other radicals on cellular macromolecules and
that can act as biomarkers of oxidative stress, including that mediated
by iron
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123O’Donnell and Freeman 2001) production or protein cys-
teine nitrosylation (Lancaster 2008; Landino 2008; Vaz and
Augusto 2008) that can provide a means of their detection
downstream. Some of these are shownin Fig. 2. A key point
here is that despite the widespread and uncritical use of the
term ROS to describe any ‘Reactive Oxygen Species’, most
such as superoxide and peroxide are not terribly reactive, in
contrast to the hydroxyl radical (and peroxynitrite) which is,
and unliganded iron is required for hydroxyl radical
production in the Fenton reaction. Hence the focus on
unliganded iron rather than the more nebulous ROSs, albeit
that (su)peroxide is necessarily involved.
Clearly the occurrence of these activities leads to the
(more or less irreversible) formation of a variety of sub-
stances that can act as biomarkers of these activities (Kell
2009a), and such oxidised compounds are represented by
both small and macro-molecules. For instance, 8-hydroxy-
20-deoxyguanosine (8-OHdG) (ChEBI 40304) also referred
to as its tautomer 8-oxo-7,8-dihydro-2’-deoxyguanosine
(8-oxodG) (HMDB03333) is produced when the hydroxyl
radical reacts with DNA and damages it (e.g. Bal and
Kasprzak 2002; Burrows and Muller 1998; Cooke et al.
2003, 2008; Lloyd et al. 1998; Loft and Poulsen 1996;
Orhan et al. 2004; Shi et al. 2003; Toyokuni and Sagripanti
1996; Valavanidis et al. 2009; Valko et al. 2005), and
body-iron status correlates rather strongly with its
production or urinary excretion (Agarwal et al. 2004;
Broedbaek et al. 2009; Fujita et al. 2007a, 2009; Gac-
kowski et al. 2002; Hori et al. 2010; Kang et al. 1998; Kuo
et al. 2008; Maruyama et al. 2007; Nakano et al. 2003;
Toyokuni and Sagripanti 1996; Tuomainen et al. 2007;
Valavanidis et al. 2005). The data in (Hori et al. 2010)
relating urinary 8-OHdG levels to serum ferritin concen-
trations are particularly striking, and I have digitised them
(cf. Pettifer et al. 2009 for pointers to automated ways of
doing this in the future) and replotted some of them in
Fig. 3.
Ferritin levels (a common measure of body iron stores)
are also widely associated with disease development/
severity/ poor outcomes (e.g. Alissa et al. 2007; Armand
et al. 2007; Bartzokis et al. 2007; Braun et al. 2004;
Bugianesi et al. 2004; Chen et al. 2006; Choi et al. 2005;
Double et al. 2000; Fargion et al. 2001; Ferna ´ndez-Real
et al. 2002; Ford and Cogswell 1999; Forouhi et al. 2007;
He et al. 2007; Hubel et al. 2004; Ishizaka et al. 2005; Jehn
et al. 2004, 2007; Kaur et al. 2007; Kiechl et al. 1997; Lee
et al. 2006f; Lim et al. 2001; Rayman et al. 2002; Rouault
2006; Salonen et al. 1992; Sheth and Brittenham 2000;
Tuomainen et al. 1998; Valenti et al. 2007; Wilson et al.
2003; You et al. 2003; You and Wang 2005) (Adam-
kiewicz et al. 2009; Baune et al. 2010; Busca et al. 2010;
DePalma et al. 2010; Ferrara et al. 2009; Ferrucci et al.
2010; Gamberini et al. 2008; Goodall et al. 2008; Inati
et al. 2010; Kaysen 2009; Knovich et al. 2009; Kolberg
et al. 2009; Lecube et al. 2008; Lim et al. 2010; Mateo-
Gallego et al. 2010; McNeill et al. 2008; Menke et al. 2009;
Qureshi et al. 2008; Rajpathak et al. 2009; Shariﬁ
et al. 2008; Skinner et al. 2010; Song et al. 2009;
Storey et al. 2009; Sun et al. 2008; Tsimikas et al. 2009;
Valenti et al. 2010; Walker et al. 2010; Wang et al. 2010b;
Yoneda et al. 2010; Zandman-Goddard and Shoenfeld 2008),
thoughnotethatmostassaysarefortheproteinitself,andnot
forthe full moleculeincluding any iron that it may sequester
effectively (Balla et al. 1992; Hintze and Theil 2006; Theil
2007) or otherwise.
Although iron is most commonly bivalent, Fe(II), or
trivalent, Fe(III), this simple statement does not remotely
cover the relevant chemistry and speciation that are nec-
essary to recognise what forms of ‘iron’ may be safe and
which are likely to catalyse damaging reactions. The ﬁrst
issue is that at neutral pH Fe(III) is more or less insoluble,
and in aerobic environments it is necessary to chelate the
otherwise ‘free’ Fe(III) with appropriate chelators or sid-
erophores (especially for microbes, e.g. Andrews et al.
2003; Barry and Challis 2009; Cornelis and Andrews 2010;
de Carvalho and Fernandes 2010; Haas et al. 2008; Johnson
2008; Miethke and Marahiel 2007; Raymond et al. 2003;
Sandy and Butler 2009; Wandersman and Delepelaire
2004; Winkelmann 2002). These siderophores—secreted as
are other bacterial pheromones (Kell et al. 1995)—typi-
cally have extremely tight binding constants (Kf [ 10
30,
e.g. Clifton et al. 2009; Loomis and Raymond 1991) and
can solubilise and sequester iron such that it can be inter-
nalised via suitable transporter molecules within the
plasma membrane (Stintzi et al. 2000).
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Fig. 3 Very strong relationship between serum ferritin concentra-
tions and urinary concentrations of the DNA damage/oxidative stress
marker 8-hydroxy-20-deoxyguanosine. Data are replotted from Fig. 1
of Hori et al. (2010)
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123Iron contains up to six individual chelation sites,
arranged octahedrally, and ligands can typically satisfy
them partially (i.e. some ligands are bidentate or tridentate
and need three or two molecules for full liganding/activity)
or fully i.e. are hexadentate. Since iron cannot be trans-
muted into any other substance, the only way to stop the
damaging activity of free or partially liganded ‘iron’ is
to ensure that all of its six possible liganding sites are
satisﬁed, whether by endogenous chelators or those
added from the diet or as pharmaceuticals. Put another
way, it is not simply enough to know that ‘iron’ is present
at an adequate level but that it is available in a suitably
liganded form. Anaemia can be caused by poor liganding
as well as by an actual shortage of ‘iron’ itself. Note too
that partial chelation in the presence of an antioxidant
agent such as ascorbate (vitamin C) can in fact make
ascorbate (or other reducing agent) act as a pro-oxidant and
thus actually promote the production of OH
• radicals in the
presence of inappropriately or inadequately liganded Fe(II)
(Allen and Cornforth 2009;F a ´bia ´n and Csorda ´s 2003;
Halliwell 2009; Hininger et al. 2005; Lachili et al. 2001;
Long et al. 2000; Miller et al. 1990; Reif 1992; Sugihara
et al. 1999). This very likely explains the often and indeed
surprisingly disappointing clinical results obtained when
using antioxidants alone (Bjelakovic et al. 2008; Giustarini
et al. 2009; Kell 2009a; Miller et al. 2005).
The above facts are well known (e.g. Halliwell and
Gutteridge 2006; Weinberg 2004), and I discussed them at
length in a recent and wide-ranging review (Kell 2009a).
My purpose here is to look more closely at the evidence
that they are part of the sequelae of a number of predis-
positions to cellular and organismal death (whether by
necrosis or apoptosis) that follow from a large variety of
initial ‘insults’ or distal causes, whether of genetic or
Fig. 4 A mind map (Buzan 2002) setting out the structure of this review. To read this start at ‘‘1 o’clock’’ and move outwards and clockwise
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123environmental origin (or both). While, as a systems prop-
erty, many other cellular processes contribute measurably
to any speciﬁc activity, I suggest, in all the disparate
cases I review, that it is the binding of poorly liganded
iron (mainly bivalent) to inappropriate cellular struc-
tures that serves to generate this catalytic activity,
albeit that the overall manifestations may differ at a
physiological level, and I here review what evidence is
available. This basic suggestion can be tested explicitly
more or less easily. I suggest further that it is this ongoing,
autocatalytic activity based on positive feedback that is
responsible for the really large-scale damage, leading to
organismal death, that can occur in affected cells, tissues,
organs and organisms. This analysis also suggests an
important role for iron chelation as part of combination
approaches in the acute and chronic therapy of these
conditions. An overview of this article is given as a Mind
Map (Buzan 2002) in Fig. 4.
Note that I do recognise that other transition and poly-
valent metal ions (Al
n?,C r
n?,C u
n?,M n
n?,S e
n?,Z n
n?
etc.) may also contribute to the kinds of process I describe.
However, for reasons of simplicity, focus, and because of
the natural abundance of this metal in biological systems, it
is ‘iron’ on which I shall concentrate. As previously (Kell
2009a), I use the term ‘iron’ to include iron of any
valencies or speciation, unless speciﬁed otherwise.
Since the role of iron is obvious in cases of primary
diseases of iron overload, such as hereditary haemochro-
matosis (e.g. Camaschella and Merlini 2005; Ellervik et al.
2007; Gan et al. 2010; Limdi and Crampton 2004; Mair
and Weiss 2009; Marx 2002; McLaren and Gordeuk 2009;
Pantopoulos 2008; Papanikolaou and Pantopoulos 2005;
Pietrangelo 2006;W e i s s2010), thalassaemias (e.g. Borgna-
Pignatti et al. 2005; Camaschella and Merlini 2005;
Cao and Galanello 2010; Cohen et al. 2004; Gattermann
2009; Lam et al. 2008; Li et al. 2010; Mohkam et al. 2008;
Peng et al. 2008; Taher et al. 2010; Vichinsky et al. 2005)
and myelodysplastic syndrome (e.g. Cazzola et al. 2008;
Cuijpers et al. 2010; Dreyfus 2008; Gattermann 2008;
Greenberg 2006; Greenberg et al. 2008; Jabbour et al.
2009;J a ¨dersten and Hellstro ¨m-Lindberg 2010; Leitch
2007; Mahesh et al. 2008; Malcovati 2009; Porter et al.
2008; Wimazal et al. 2009), I largely ignore this literature.
However, I recognise that the sequelae of iron overload,
especially various kinds of organ failure, share many
similarities to those I describe below, consistent with the
role of iron in these other cases where its involvement has
been less widely recognised. Clearly the commonality of
any speciﬁc effect with those of known iron overload
(Dever et al. 2010) might give strong hints for the
involvement of iron in speciﬁc toxicological processes.
The literature survey at the time of initial submission for
review extended to 14 June, 2010.
To start our survey, we look at the consequences of an
acute cerebral infarction or stroke.
Stroke
Stroke is a term used to describe the destruction of brain
cells, typically following a temporary blockage in blood
ﬂow (ischaemia-reperfusion injury) or an intra-cranial
haemorrhage. The extent of damage varies considerably,
and can be exacerbated because affected cells can release
inﬂammatory cytokines that activate other cells in a similar
way, providing a positive autocatalytic effect and leading
to spreading of the damage. It is this secondary spreading
that is especially damaging, but because it is slower
(4–7days), it also affords the opportunity for therapeutic
intervention (Qureshi et al. 2009). It is now clear that iron
is intimately involved (Armengou and Davalos 2002;
Bailey et al. 2006; Bishop and Robinson 2001; Chang et al.
2005;D a ´valos, et al. 1994; Demougeot et al. 2004; Ferro
and Da ´valos 2006; Garouﬁ et al. 2006; Gillum et al. 1996;
Lee et al. 2006e; Marniemi et al. 2005; Mascitelli and
Pezzetta 2006; Mehta et al. 2004; Mu et al. 2005;
Nakamura et al. 2006; Saxena et al. 2005; Selim and Ratan
2004; Switzer et al. 2006; Wagner et al. 2003; Wu et al.
2003; Zuliani et al. 2006; Adams 2007; Altamura et al.
2009; Assenza et al. 2009; Basak et al. 2008; Bosomtwi
et al. 2008; Carbonell and Rama 2007; Cho et al. 2007;
Ekblom et al. 2007; Hanson et al. 2009; Heckl 2007; Helal
2008; Jolkkonen et al. 2007; Justicia et al. 2008; Kaushal
and Schlichter 2008; Kim et al. 2008a; Kobayashi et al.
2008; Lou et al. 2009; Maguire et al. 2007; Mazumdar et al.
2007;M e h d i r a t t ae ta l .2008;M i l l a ne ta l .2007, 2008;
Millerot-Serrurot et al. 2008; Nighoghossian et al. 2008;
O’Rourke et al. 2008; Ratan et al. 2008; Ross and Meschia
2009; Saleh et al. 2007; Santhosh et al. 2009; Verduzco and
Nathan 2009; Walters and Rye 2009; Weng et al. 2008),
whether by release from (ferritin in) cells or from the haem
of haemoglobin. Iron chelators have thus shown promise in
decreasing the sequelae of an initial stroke-inducing event
(Demougeot et al. 2004; Ferro and Da ´valos 2006; Hurn
et al. 1995; Kompala et al. 1986; Mu et al. 2005; Patt et al.
1990; Prass et al. 2002; Selim and Ratan 2004; Soloniuk
et al. 1992; White et al. 1988; Chen-Roetling et al. 2009;
Gu et al. 2009; Hanson et al. 2009; Hua et al. 2008;
Mazumdar et al. 2007;M e ´thy et al. 2008; Millerot-Serrurot
et al. 2008; Mirre et al. 2010; Okauchi et al. 2009, 2010;
Ratan et al. 2008; Robinson et al. 2009; Selim 2009;
Verduzco and Nathan 2009), providing further evidence for
the primary importance of iron in causing injury.
While stroke is a sudden occurrence, albeit with sec-
ondary consequences, a number of neurodegenerative dis-
eases are rather more long term in their development, and
Arch Toxicol (2010) 84:825–889 829
123we now look at several, each of which is seen to involve
iron intimately.
Huntington’s disease
The pathology of HD reveals striking neurodegeneration in
the corpus striatum and shrinkage of the brain, leading to
its most prominent manifestation, viz. movement disorders
or chorea (Bhidayasiri and Truong 2004). Huntington’s
disease occurs via the addition of trinucleotide CAG
repeats within exon 1 of the relevant gene, encoding
(poly)glutamine (polyQ) repeats in the huntingtin protein
(htt) and leading to a gain of (toxic) function (Bauer and
Nukina 2009; Gusella and MacDonald 2000; Imarisio et al.
2008; Quintanilla and Johnson 2009). The number of these
repeats determines both the time of onset of observable
disease (more repeats meaning earlier onset) (Perutz and
Windle 2001; Ross 1995; Walters and Murphy 2009),
accounting for 70% of the variance (Imarisio et al. 2008),
and the disease severity, implying that it is indeed the
polyglutamines themselves that are the chief culprits. Some
of the polyQ-containing huntingtin proteins can also
aggregate to form inclusion bodies, and aggregation and
neurodegeneration can in part be related (Chopra et al.
2007; Cowan et al. 2003; Michalik and Van Broeckhoven
2003; Nagai et al. 2003; Wang et al. 2005, 2009; Zhang
et al. 2005a). Now the evidence for the involvement of
poorly liganded iron in a wide variety of neurodegenerative
diseases is overwhelming (e.g. Benarroch 2009; Bishop
et al. 2010a; Brown 2009a; Friedman et al. 2007; Jellinger
1999; Ke and Qian 2003; Kell 2009a; Lee et al. 2006a;
Perez and Franz 2010; Thompson et al. 2001; Youdim et al.
2004b; Zecca et al. 2004), and the question arises as to
whether huntingtin (or, more likely, its degradation frag-
ments), containing these polyQ tracts, can catalyse oxida-
tive stress and/or hydroxyl formation directly. In an
important paper, Firdaus et al. (Firdaus et al. 2006) show
that that huntingtin inclusion bodies act as centres of oxi-
dative stress and that partially puriﬁed inclusion bodies
contain large amounts of oxidised proteins. Iron metabo-
lism is deranged in gene knockdown models of Hunting-
ton’s (Henshall et al. 2009; Lumsden et al. 2007), and
experiments with the iron chelator deferroxamine revealed
that the oxidation, localisation and structural organisation
of the inclusion bodies formed by mutant htt were indeed
irondependent. They did not demonstrate the ability of
these inclusion bodies to catalyse hydroxyl formation, but
this could easily be shown using speciﬁc assays, such as the
hydroxylation of suitable aromatics (e.g. Grootveld and
Halliwell 1986; Halliwell and Gutteridge 2006; Thomas
et al. 2009a). The iron chelator clioquinol is also protective
(Nguyen et al. 2005).
Parkinson’s disease
Parkinson’s disease (PD) results primarily from the death
of dopaminergic neurons in the substantia nigra part of the
brain and is characterised in particular by the presence of
intracytoplasmic inclusions from protein aggregates called
Lewy bodies (LB) and at the physiological level by a
variety of movement disorders (e.g. Singh et al. 2007). It is
strongly linked with oxidative stress (e.g. Alam et al. 1997;
Bu ¨eler 2009; Jenner 2003; Jenner and Olanow 1996; Kidd
2000; Mandel et al. 2003; Olivares et al. 2009; Seet et al.
2010; Van Laar and Berman 2009; Zhang et al. 1999).
Again (e.g. Berg et al. 2001; Bharath et al. 2002; Buchanan
et al. 2002; Bush 2000; Castellani et al. 2002; Double et al.
2000; Good et al. 1998; Gotz et al. 2004; Hirsch and
Faucheux 1998; Jellinger 1999; Johnson 2000; Olanow and
Arendash 1994; Ostrerova-Golts et al. 2000; Soﬁc et al.
1991; Wolozin and Golts 2002; Altamura and Muckent-
haler 2009; Andersen 2004; Barapatre et al. 2010; Baudr-
exel et al. 2010; Becker 2010; Becker et al. 2010a, b; Berg
2006, 2007; Berg and Hochstrasser 2006; Berg et al. 2006,
2008; Brar et al. 2009; Brown 2009b; Crichton and Ward
2006; Fasano et al. 2006; Friedman et al. 2007, 2009;
Ghosh et al. 2010; Hirsch 2009; Jellinger 2009; Jimenez-
Del-Rio et al. 2010; Kaur and Andersen 2004; Lee and
Andersen 2010; Levenson 2003; Mandemakers et al. 2007;
Matusch et al. 2010; Oakley et al. 2007; Salvador 2010; Shi
et al. 2010; Wayne Martin 2009; Wypijewska et al. 2010;
Yeager and Coleman 2010; Zecca et al. 2004; Zhang et al.
2005, 2010b)—there is overwhelming evidence for the
involvement of iron in this neurodegeneration. Why these
dopaminergic neurons are especially susceptible is not
entirely clear, although dopamine is capable of reacting
with iron directly to form a toxic complex (Arreguin et al.
2009; Paris et al. 2005) that probably itself catalyses
hydroxyl formation. Iron chelators inhibit these inimical
processes (Gal et al. 2006; Perez et al. 2008; Xu et al. 2008;
Youdim et al. 2004a, b; Zheng et al. 2005), including (Kaur
et al. 2003; Reznichenko et al. 2010; Youdim 2003) in the
case of a Parkinson-like disease induced (Blum et al. 2001;
Choi et al. 2009; Gal et al. 2009; Yokoyama et al. 2008)b y
1-methyl-4-phenyl-1,2,3,6-tetrahydro-pyridine (MPTP)
(ChEBI 17963). The Lewy bodies contain lipid and a
variety of proteins, including ubiquitin, neuroﬁlament,
various proteasomal elements and a-synuclein, which may
be oxidatively modiﬁed (Double et al. 2008). Ferric iron
may itself catalyse the formation of a-synuclein oligomers
(Brown 2009a; Hillmer et al. 2009; Peng et al. 2010), and
copper may also be involved (Wang et al. 2010c).
Melanins are polymers of polyphenols, especially of
L-dopamine, although neuromelanin, which also contains
oxidatively polymerised dopamine or noradrenaline with
the possible involvement of cysteinylderivatives (Fedorow
830 Arch Toxicol (2010) 84:825–889
123et al. 2005), is of special interest here. The substantia nigra
also contains a substantial amount of the dark, insoluble
polymeric pigment neuromelanin, and this has been shown
directly to bind (and release) iron in high amounts (Double
et al. 2003a, b; Fasano et al. 2006; Faucheux et al. 2003;
Gerlach et al. 2003, 2008; Shamoto-Nagai et al. 2006), and
thereby to produce an iron-loaded form that seems to serve
as a reservoir catalysing (hydroxyl) radical formation and
whose amounts correlate with PD. In this case, the in vitro
experiments have been done, and incubation of human
neuromelanin with iron in vitro stimulates oxidative tissue
damage (Ben-Shachar et al. 1991; Double et al. 2003a;
Gerlach et al. 2008).
AnotherdarkpigmentcommonlyobservedinPDpatients
(andotherneurodegenerativediseases)islipofuscin(Double
et al. 2008; Jung et al. 2007; Terman and Brunk 2004).
Lipofuscin too consists of lipids and oxidised proteins, often
crosslinked by oxidised lipid derivatives such as (E)-4-
hydroxy-non-2-enal (ChEBI 58968) and can adsorb high
contents of metals (including iron) of up to 2% by weight
(Jung et al. 2007). It is typically formed in lysosomes from
degrading mitochondria (Terman et al. 2006a), themselves
richinmetalloproteins,andtheinabilityofcellstodegradeit
means that (purportedly) non-dividing cells (such as brain
tissue) simply accumulate it as cells age (Terman and Brunk
2004, 2006). This arguably explains why non- or rarely-
dividing tissues such as brain tissues are particularly sus-
ceptible, though note the important and increasing evidence
(e.g. Abrous et al. 2005; Christie and Cameron 2006; Demir
et al. 2009; Fuchs and Gould 2000;G o ¨tz and Huttner 2005;
Gould 2007; Imayoshi et al. 2009; Leuner et al. 2007; Lledo
et al. 2006; Ohnuma and Harris 2003; Taupin 2007; Zhao
et al. 2008) for considerable turnover—neurogenesis—in at
least some regions of the brain. The autocatalytic nature of
the process—lipofuscin loaded with iron catalyses more
lipofuscin production—is especially dangerous and can (as
one would predict) be inhibited using appropriate iron che-
lators (Persson et al. 2003). Iron chelation also assists neu-
rogenesis (Nowicki et al. 2009).
Thus, as with Huntington’s, Parkinson’s disease is
clearly characterised by all the hallmarks of hyperactive
hydroxyl radical generation, leading to cell death and
destruction, in this case mainly, it would seem (Chen et al.
2007; Chiueh et al. 2000; Ekshyyan and Aw 2004; Jellinger
2002; Jenner 2003; Jenner and Olanow 1996; Kermer et al.
2004; Levenson 2005; Loh et al. 2006; Mandel et al. 2005;
Mattson 2006; Okouchi et al. 2007; Xu et al. 2008a;
Yasuda and Mochizuki 2010), by apoptosis.
Gaucher’s disease
Gaucher’s disease is an autosomally recessive inborn error
of metabolism due to deﬁciency of a lysosomal enzyme,
glucocerebrosidase (GBA), resulting in the accumulation
of glucocerebroside in large macrophages throughout the
reticuloendothelial system, leading to various neuronopa-
thies. Given that the lysosome is the site of most labile iron
in the cell (Fakih et al. 2008; Gorria et al. 2008; Kurz et al.
2004, 2008a, b; Persson 2005; Tenopoulou et al. 2007;
Terman et al. 2006b; Yu et al. 2003), it is also of interest
that there is an increased frequency of mutations in the
gene encoding GBA among patients with Parkinson’s
disease (e.g. Aharon-Peretz et al. 2004; Clark et al. 2007;
Gan-Or et al. 2008; Lwin et al. 2004), and vice versa
(Sidransky et al. 2009). Iron dysregulation is also well
established in Gaucher’s disease (Finch et al. 1986; Lee
et al. 1967, 1977; Lorber 1960, 1970; Morgan et al. 1983;
Schiano et al. 1993; Weisberger et al. 2004). This recog-
nition of the role of iron dysregulation in Gaucher’s disease
may offer novel therapeutic approaches.
Alzheimer’s disease
Alzheimer’s disease (AD), the commonest of the neuro-
degenerative disease of ageing, shares many similarities
with Huntington’s and Parkinson’s diseases, not least the
extensive evidence for the role of oxidative stress (e.g.
Butterﬁeld et al. 2007; Christen 2000; DiMauro and Schon
2008; Good et al. 1996; Milton 2004; Miranda et al. 2000;
Moreira et al. 2009; Nunomura et al. 2001, 2006; Reddy
and Beal 2008; Reddy et al. 2009; Rottkamp et al. 2000;
Smith et al. 1996, 2000; Zhu et al. 2007) and of iron (e.g.
Adlard and Bush 2006; Avramovich-Tirosh et al. 2007a;
Becker et al. 2010b; Bishop et al. 2002; Bla ´zquez et al.
2007; Bolognin et al. 2009b; Brar et al. 2009; Bush 2000,
2003, 2008; Casadesus et al. 2004; Castellani et al. 2007;
Collingwood and Dobson 2006; Collingwood et al. 2008;
Connor and Lee 2006; Ding et al. 2009; Doraiswamy and
Finefrock 2004; Gerlach et al. 1994; Good et al. 1996;
Hegde et al. 2009; Honda et al. 2004; Jellinger et al. 1990;
Jellinger 2009; Kala et al. 1996; Lehmann et al. 2006;
LeVine 1997; Lovell et al. 1998; Malecki and Connor
2002; Mandel et al. 2007; Markesbery 1997; Markesbery
and Lovell 1998; Mascitelli et al. 2009; Olanow and
Arendash 1994; Ong and Farooqui 2005; Quintana et al.
2006; Rival et al. 2009; Robson et al. 2004; Silvestri and
Camaschella 2008; Smith et al. 1997a, 2010; Tabner et al.
2005; Thomas and Jankovic 2004; Thompson et al. 2001;
Valko et al. 2005; Zatta et al. 2009; Zecca et al. 2004;
Zheng et al. 2005). It is especially noteworthy that iron
correlates with disease severity as measured by cognitive
ability (Ding et al. 2009;G o ´mez Ravetti et al. 2010; Grossi
et al. 2009; Lavados et al. 2008; Perez et al. 2010; Smith
et al. 2010). AD is characterized by the loss of neurons in
the cognitive centres of the brain and by the presence of
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(Ab) plaques (e.g. Dong et al. 2003; Scott and Orvig 2009)
and neuroﬁbrillary tangles within neurons (Shcherbatykh
and Carpenter 2007).
Again, there is evidence that insoluble polymers
(ﬁbrillary tangles) of proteins such as the b-amyloid can
bind iron (Castellani et al. 2007; Dickens and Franz 2010;
Exley 2006; Good et al. 1992; Jiang et al. 2009; Mancino
et al. 2009; Rival et al. 2009; Sayre et al. 2000b; Smith
et al. 2007) and thereby act in an autocatalytic manner to
promote further radical production and oxidative stress.
There is a also relationship between the ability to bind
haem and neurotoxicity (Atamna 2009; Atamna et al.
2009), and (HFE) mutations that cause haemochromatosis
increase the susceptibility to AD (Bartzokis et al. 2010;
Candore et al. 2003; Combarros et al. 2003; Connor and
Lee 2006; Haacke et al. 2005; Kauwe et al. 2010; Lleo ´
et al. 2002; Moalem et al. 2000; Pulliam et al. 2003;
Robson et al. 2004; Sampietro et al. 2001), especially when
in the presence of the APOE4 allele (Pulliam et al. 2003).
(HFE mutations also increase susceptibility to PD (Biasi-
otto et al. 2008; Dekker et al. 2003)—but cf. (Aamodt et al.
2007)—and to ALS (Ellervik et al. 2007)).
Importantly, iron chelators have been shown to
ameliorate the development of ﬁbril formation/neurodegen-
eration/dementia/AD (Amit et al. 2008; Avramovich-
Tirosh et al. 2007a; Bandyopadhyay et al. 2006; Barnham
et al. 2004; Biran et al. 2009; Bolognin et al. 2009a;
Crapper McLachlan et al. 1991; Cuajungco et al. 2000;
Faux et al. 2010; Finefrock et al. 2003; Liu et al. 2009b, c,
2010; Mancino et al. 2009; Mandel 2007, 2008;
Reznichenko et al. 2006; Scott and Orvig 2009; Weinreb
et al. 2009a; Zheng et al. 2005). Although this fact rarely
appears in papers setting out therapeutic options for
preventing (or at least ameliorating the progress of) AD,
this already considerable literature suggests that trials using
modern iron chelators would be of worth.
Amyotrophic lateral sclerosis (ALS, Lou Gehrig’s
disease)
ALS is another neurodegenerative disease in which iron
has been strongly implicated (and thus the same kinds of
mechanism as described previously) (Bush 2000; Carri
et al. 2003; Cozzolino et al. 2008; Goodall et al. 2008;
Jeong et al. 2009; Kasarskis et al. 1995; Mattson 2004;
Migliore et al. 2005; Molﬁno et al. 2009; Qureshi et al.
2008; Reynolds et al. 2007; Sadrzadeh and Saffari 2004;
Sayre et al. 2000a; Scott and Orvig 2009; Spasojevic ´ et al.
2010; Sutedja et al. 2007; Wang et al. 2004). Again, the
clear beneﬁts of iron chelators in mouse models (Jeong
et al. 2009; Petri et al. 2007) and elsewhere (Avramovich-
Tirosh et al. 2007b; Bolognin et al. 2009a) would seem to
merit trials in humans known to be at risk. Long-standing
associations of some forms of ALS with mutations in genes
coding for superoxide dismutase 1 (e.g. Dalle-Donne 2007;
Pasinelli and Brown 2006; Rosen et al. 1993; Vucic and
Kiernan 2009; Wijesekera and Leigh 2009) are consistent
with this, and recent genetic associations (e.g. Kwiatkowski
Jr. et al. 2009; Valdmanis et al. 2009; Vance et al.
2009) include one with optineurin (Maruyama et al. 2010)
that together with other evidence implies an interaction
with NF-jB (see later) leading to the downstream effects of
apoptotic neuronal cell death.
Friedreich’s ataxia
Friedreich’s ataxia is another neurodegenerative disease
caused by the insertion of a trinucleotide repeat (or occa-
sionally a missense mutation) in the gene encoding a pro-
tein called frataxin (Adibhatla and Hatcher 2010; Babady
et al. 2007; Becker and Richardson 2001; Bencze et al.
2006; Chakravarty 2003; Gonza ´lez-Cabo et al. 2009; Palau
2001; Pandolfo 2009; Patel and Isaya 2001; Puccio 2009;
Ro ¨tig et al. 2002; Santos et al. 2010; Sheftel et al. 2010).
Driven not least by studies in bacteria and lower eukaryotes
(Ayala-Castro et al. 2008; Becker and Richardson 2001;
Bulteau et al. 2007; Cavadini et al. 2000; Cook et al. 2006;
De Freitas et al. 2003; Foury 1997; Foury and Cazzalini
1997; Foury and Talibi 2001; Gonza ´lez-Cabo et al. 2005;
Irazusta et al. 2006, 2008; Knight et al. 1999; Pastore et al.
2007;V a ´zquez-Manrique et al. 2006; Wang and Craig
2008; cf. Seguin, et al. 2010), it is now understood that
frataxin is a mitochondrial iron chaperone protein (Atkinson
and Winge 2009; Ba et al. 2009; Babady et al. 2007;
Bencze et al. 2007; Cavadini et al. 2002; Correia et al.
2008; Gakh et al. 2006; Haugen et al. 2010; Huang et al.
2008a; Huang et al. 2009; Karlberg et al. 2006; Kondapalli
et al. 2008; Lill 2009; Lill and Muhlenhoff 2008; Lu and
Cortopassi 2007; MacKenzie et al. 2008; Mandemakers
et al. 2007; Marmolino and Acquaviva 2009; Napier et al.
2005; Napoli et al. 2006; O’Neill et al. 2005; Pandolfo
2009; Pandolfo and Pastore 2009; Pastore et al. 2007;
Reddy 2008; Schagerlo ¨f et al. 2008; Sparaco et al. 2009;
Wilson 2006; Zanella et al. 2008) involved in the safe
insertion of Fe(II) during the production of Fe–S centres in
the mitochondrial respiratory chain (Anderson et al. 2005).
The defect thus leads to the liberation of mitochondrial iron
(Huang et al. 2009; Popescu et al. 2007; Richardson et al.
2009a). Fenton chemistry is strongly implicated (Park et al.
2002; Sturm et al. 2005), as the attenuation of H2O2 pro-
duction (but not of superoxide) (Anderson et al. 2005)
ameliorates the disease (Anderson et al. 2008). As would
be expected, appropriate iron chelation may have
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et al. 2009; Goncalves et al. 2008; Kakhlon et al. 2010;
Lim et al. 2008; Marmolino and Acquaviva 2009; Santos
et al. 2010; Schulz et al. 2009; Sohn et al. 2008). This very
clear molecular picture underlines strongly the problems of
iron release leading to cell death and destruction.
Multiple sclerosis
MS is an inﬂammatory demyelinating autoimmune disease
affecting the CNS. While its underlying causes remain
uncertain, and do not seem to have a signiﬁcant genetic
component (Baranzini et al. 2010; Oksenberg et al. 2008;
Ramagopalan et al. 2008), ROS are certainly implicated
(Adibhatla and Hatcher 2010), and antioxidant therapies
may be useful (Mirshaﬁey and Mohsenzadegan 2009). It is
at least plausible that part of the demyelination is caused by
ROS and in particular hydroxyl radicals, and it is thus of
much interest that iron dysregulation and/or deposition
have indeed been implicated directly (Adams 1988; Bakshi
et al. 2000, 2001, 2002, 2008; Bermel et al. 2005; Brass
et al. 2006a, b; Ceccarelli et al. 2009, 2010; Chard and
Miller 2009; Craelius et al. 1982; Drayer et al. 1987; Eissa
et al. 2009; Exley et al. 2006; Filippi and Agosta 2009;G e
et al. 2007; Grimaud et al. 1995; Haacke et al. 2005, 2009,
2010; Hammond et al. 2008; He and Yablonskiy 2009;
Khalil et al. 2009; LeVine and Chakrabarty 2004; Neema
et al. 2007a, b, 2009a, b; Pirko et al. 2009; Sayre et al.
2005; Schenck and Zimmerman 2004; Simka and Rybak
2008; Singh and Zamboni 2009; Stankiewicz et al. 2007;
Tjoa et al. 2005; Walter et al. 2009; Zamboni 2006;
Zivadinov and Bakshi 2004; Zivadinov and Minagar 2009).
While the extent of causality of the iron dysregulation in
MS is not yet established, it is highly pertinent that iron
chelators have been shown to suppress disease progression
in experimental autoimmune encephalomyelitis (EAE), an
animal model of multiple sclerosis (Bowern et al. 1984;
Mitchell et al. 2007; Pedchenko and LeVine 1998). To say
the least, the question of the involvement of iron in the
human disease would seem to need pursuing with some
urgency.
Age-related macular degeneration
While this review is intended to be much more circum-
scribed than the previous one (Kell 2009a), there are some
pertinent diseases in which my understanding has improved
signiﬁcantly, and age-related macular degeneration is one
such. Age-related macular degeneration (AMD) (Rattner
and Nathans 2006) is recognised as the leading cause of
blindness and visual disability in the elderly in developed
countries (Fine 2005; Harvey 2003; Lotery and Trump
2007; Tielsch et al. 1995). Interestingly, despite the rela-
tively modest impact of genome-wide association studies
to date (Maher 2008; Moore et al. 2010), and notwith-
standing their promise as their statistical power improves,
80% of the variation in susceptibility to AMD is said to be
explainable (Collins 2010) (and see e.g. Chu et al. 2008)
though cf. e.g. (Chen et al. 2010; Hadley et al. 2010; Katta
et al. 2009; Neale et al. 2010; Patel et al. 2008; Sobrin et al.
2010) by just two genes concerned with inﬂammation
combined with two environmental factors (smoking and
obesity). The environmental factors can certainly be related
to iron dysregulation. Indeed, as previously discussed, iron
is signiﬁcantly implicated in AMD (and other related dis-
eases such as glaucoma) (Blasiak et al. 2009; Cai et al.
2000; Charkoudian et al. 2008; Chen et al. 2009; Chowers
et al. 2006; Dentchev et al. 2005; Dunaief 2006; Garcı ´a-
Castin ˜eiras 2010; Goralska et al. 2009a, b, c; Hahn et al.
2003, 2004; He et al. 2007; Loh et al. 2009; Richer et al.
2002; Wong et al. 2007), iron chelation may help to reverse
the process (Voloboueva et al. 2007), and dietary and other
antioxidants are also protective (see Tan et al. 2008; Wang
et al. 2009).
Prion diseases: including transmissible spongiform
encephalopathies and Creutzfeldt–Jakob disease
A particularly striking set of diseases, where the down-
stream events manifest as extreme cellular destruction
leading to large areas of (brain) tissue disappearing com-
pletely, are represented by the prion diseases, in particular
the TSEs including bovine spongiform encephalopathy
(BSE) (e.g. Aguzzi et al. 2008a; Aguzzi and Heikenwa ¨lder
2006; Caughey and Baron 2006; Caughey and Lansbury
2003; Linden et al. 2008) and scrapie (e.g. Bulgin and
Melson 2007; Hur et al. 2002; Roostaee et al. 2010;
Wisniewski and Sigurdsson 2007), kuru (Gajdusek 2008;
McLean 2008) and CJD (e.g. McLean 2008; Peden and
Ironside 2004) (note too the co-location of amyloid plaques
and spongiform degeneration in CJD, Ghoshal et al. 2009).
Now it is well known that prion diseases are caused in
part (or at least accompanied by) the conversion of the
prion protein PrP from its normal form PrP
C to a con-
formationally distinct version PrP
Sc and that the latter can
autocatalyse this conversion (Aguzzi and Heikenwa ¨lder
2006; Aguzzi et al. 2008b; Prusiner 1998, 2001; Tamgu ¨ney
et al. 2008; Watts and Westaway 2007). However, PrP
Sc
levels are in many cases poorly correlated with prion dis-
ease progression, suggesting that it is necessary but not
sufﬁcient; ‘something else’ is required (Caughey and Baron
2006). Equally, it is far from clear how a simple confor-
mational change of a protein leads to the vacuolation or
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strong et al. 2001; Chung et al. 1999; Crozet et al. 2008;
Diedrich et al. 1991; Foster et al. 2001; Julius et al. 2008;
Kourie 2002; Mallucci et al. 2003; Mallucci et al. 2007;
Miele et al. 2001; Sakudo and Ikuta 2009a, b; Westaway
et al. 1994; Williams et al. 1997) (formation of holes) in
brain tissue characteristic of late-stage prion disease (and
indeed of Alzheimer’s (Erkinjuntti et al. 1996; Sakudo and
Ikuta 2009a). The question then arises as to whether it is
possible that PrP
Sc modiﬁes iron metabolism in an unfa-
vourable way (and/or vice versa), not least since prion
proteins bear phylogenetic relationships to the ZIP family
of metal ion transporters (Schmitt-Ulms et al. 2009).
Building on earlier work relating prion biology with
(especially) iron-induced oxidative stress (e.g. Bareggi
et al. 2009; Barnham et al. 2006; Basu et al. 2007; Choi
et al. 2006; Fernaeus et al. 2005a, b; Fernaeus and Land
2005; Iwamaru et al. 2008; Kim et al. 2000, 2001, 2007;
Lee et al. 2007; Lehmann 2002; Milhavet and Lehmann
2002; Pamplona et al. 2008; Park et al. 2008; Petersen et al.
2005; Pollera et al. 2005; Rana et al. 2009; Stegmann and
Grohmann 2003; Westergard et al. 2007; Wong et al.
2001), this is exactly what Singh and colleagues (Singh
et al. 2009a, b, c, 2010a, b) have now demonstrated, which
is that the ‘something else’ (Kell 2009a, b) is (as so often)
an imbalance in iron metabolism. They start by showing
(Singh et al. 2009c) that even normal PrP
C mediates cel-
lular iron uptake and transport and that mutant PrP forms
alter cellular iron levels differentially.
PrP
C binds iron tightly, and this helps effect its con-
version to PrP
Sc (Singh et al. 2010a, b). Singh et al. (2009a)
showed that PrP
Sc can sequester cellular iron in insoluble
PrP
Sc–ferritin complexes, making it bio-unavailable, and
that this leads to an upregulation of iron uptake via trans-
ferrin and its receptor, leading to an overall iron excess in
brain tissue. This was true for both scrapie and sporadic
Creutzfeldt–Jakob disease, and stresses that it is not only
the total amount of Fe(II) and Fe(III) that matter but their
speciation. Mice knocked out for PrP also show derange-
ment in iron metabolism (Singh et al. 2009b), and given
what we know already (Kell 2009a) this leads to many
obvious predictions of other diseases (Altamura and
Muckenthaler 2009; Granic et al. 2009; Reddy et al. 2009;
Serra et al. 2009) to which they might be susceptible. It has
not yet been shown that PrP
Sc–ferritin complexes catalyse
OH
• production directly, but if this is increased in diseased
brains this continuous, autocatalytic spewing out of toxic
OH
• radicals would clearly be able to account for the
massive damage observed. A systems biology approach by
Hwang et al. (Hwang et al. 2009) also found many genes of
iron metabolism modiﬁed in prion disease. There is little
doubt that all these new ﬁndings about the role of iron (and
other metals, e.g. Brown et al. 1997) open up many new
inroads into understanding the important role of iron in prion
diseases, and thereby novel therapeutic options involving
both anti-oxidants and cell-permeable iron chelators. Some
of these new ideas and ﬁndings are illustrated in Fig. 5.
Finally, here, it is worth pointing up the evidence for the
role of iron and its metabolic dysregulation in the oxidative
stress-mediated aetiology of scrapie (Choi et al. 2006;
Fernaeus et al. 2005a; Fernaeus and Land 2005;
Gudmundsdo ´ttir et al. 2006;K i me ta l .2000, 2007;P a m p l o n a
et al. 2008; Singh et al. 2009a, 2010a, b; Wong et al.
2001a, b; Yun et al. 2006), a prion disease of sheep and
goats (Bulgin and Melson 2007; Hur et al. 2002) and of
CJD (Choi et al. 2006; Freixes et al. 2006; Petersen et al.
2005; Singh et al. 2009a, 2010a, b). As such, the use of
geostatistics relating the variation of metals present in soils
to prion disease prevalence is also a powerful tool here
(e.g. Gudmundsdo ´ttir et al. 2006; Imrie et al. 2009; Purdey
2000; Stevens et al. 2009).
Iron deposition and disease: cause or effect? The case
of atherosclerosis
I have implied that the role of unliganded iron is causative
of a variety of sequelae, but sometimes this is hard to infer
as the networks in which iron is involved are multiple and
complex (hence the need for a systems approach—see
later), and often simple one-time snapshots of covariates do
not permit the inference of causality. However, one effect
of the reaction of hydroxyl radicals (their formation cata-
lysed by unliganded iron) with proteins (or lipids) is to tend
to make those proteins (or lipids) insoluble or ﬁbrotic
(Davies 2005; Fig. 6), and if one believes that this is
+
Excess unliganded metal 
(e.g. Fen+) in brain
Redox-active metal 
(e.g. Cun+, Fen+)
ROSs including 
hydroxyl radical
PrPC with
bound Fen+/Cun+
redox-active PrPSc / ferritin
with bound Fen+/Cun+
redox-active PrPSc / ferritin
Aggregates with bound Fen+/Cun+
neurotoxicity
Gain of
toxic 
function
Loss of
protective 
function
Fig. 5 Some of the interactions between the prion protein in its two
main conformations, reactive oxygen species and iron dysregulation.
This diagram is based on Fig. 12 of (Singh et al. 2010b), and
illustrates in particular the autocatalytic nature of the ROS- and iron-
dependent conversion of PrP
C to PrP
Sc and the neurotoxicity of the
latter
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123causative, the presence of insoluble plaques should corre-
late with the presence of the iron that is seen to have caused
their formation and thereby became entrapped (and may
yet be further reactive). Because of its biomedical impor-
tance, considerable work has been performed on athero-
sclerotic lesions, which provide a very clear example.
Atherosclerosis is a progressive (and inﬂammatory) dis-
ease (Altman 2003; Binder et al. 2002; Blake and Ridker
2001;Duewelletal.2010;Dwyeretal.2004;Forrester2002,
2004; Gieseg et al. 2009; Grainger 2007; Hansson 2001,
2005;Himmelfarbetal.2002;Kibel etal.2008;Kunschand
Medford 1999; Libby 2002; Libby et al. 2002; Madamanchi
et al. 2005a, b; Mullenix et al. 2005; Nigro et al. 2006;
Packard and Libby 2008; Paoletti et al. 2004; Popa et al.
2007; Rader and Daugherty 2008; Ridker et al.et al. 2004;
Ross 1999; Schleicher and Friess 2007; Subramanian and
Ferrante 2009; Sullivan 2009; Tan and Lip 2008; Tang et al.
2009; Taqueti et al. 2006; Tedgui and Mallat 2006; van
Leuven et al. 2008; van Oostrom et al. 2004; Willerson and
Ridker 2004; Young et al. 2002) characterized by the accu-
mulationofbothoxidisedlipidsandvariousﬁbrouselements
inarteries,oftenasplaques(Lusis2000;StockerandKeaney
2004). Several lines of evidence point to the involvement of
iron in these processes:
• Both iron and oxidised lipids (de Valk and Marx 1999;
Smith et al. 1992) are found in atherosclerotic lesions
(Altamura and Muckenthaler 2009; Brewer 2007; Chau
2000; Fernandes de Godoy et al. 2007; Gajda et al.
2008; Halliwell 2009; Horwitz et al. 1998; Kazi et al.
2008; Lee et al. 1998; McRae et al. 2009; Rajendran
et al. 2007; Ramakrishna et al. 2003; Roijers et al.
2005; Smith et al. 1992; Stadler et al. 2004; Stanley
et al. 2006; Stocker and Keaney 2005; Sullivan 2009;
Watt et al. 2006; Wolff et al. 2004; Yuan and Li 2008)
• Iron depletion by dietary or other means delays the
formation of such lesions (Ferrara and Taylor 2005;
Halliwell 2009; Lee et al. 1999; Matthews et al. 1997;
Ponraj et al. 1999; Ren et al. 2005).
• There is a correlation between iron status and athero-
sclerosis (Ahluwalia et al. 2010; Chau 2000; Day et al.
2003; de Valk and Marx 1999; DePalma et al. 2010;
Gozzelino et al. 2010; Howes et al. 2000; Kallianpur
2005; Kartikasari et al. 2009; Kiechl et al. 1997;
Lapenna et al. 2007; Marx et al. 2008; McRae et al.
2009; Minqin et al. 2003; Ramakrishna et al. 2003; Ren
et al. 2003; Salonen et al. 1992; Shah and Alam 2003;
Sullivan 2007, 2009; You et al. 2003; You and Wang
2005; Zacharski et al. 2000; Zacharski and Gerhard
2003) (and zinc is protective only against subsequent
calciﬁcation, Stadler et al. 2008)
• Exogenous ferric iron is deleterious to endothelial
function (Rooyakkers et al. 2002)
• Iron chelation improves endothelial function (Altamura
and Muckenthaler 2009; Duffy et al. 2001; Halliwell
2009; Ishizaka et al. 2005; Saito et al. 2005; Thomas
et al. 2006).
• Iron levels in plaques correlate with the amount of
oxidised proteins therein (Stanley et al. 2006); indeed
in one study (Stadler et al. 2004), the EPR-detectable
iron (essentially Fe(III)) in atherosclerotic tissue was
seventeen times greater than that in the equivalent
healthy tissue. I redraw these data in Fig. 7.
It seems clear that the application of similar studies to
other diseases in which plaque formation occurs will be of
beneﬁt. Indeed, the location of iron in plaques has also
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Fig. 7 Large (17-fold) accumulation of EPR-detectable iron in
atherosclerotic plaques relative to healthy non-atherosclerotic
(‘intima’) controls. The difference is highly signiﬁcant (P =
0.0001). Data are replotted from those in Fig. 1b of Stadler et al.
(2004)
Iron (auto) catalysed plaque 
formation
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Fig. 6 Iron catalyses the formation of the hydroxyl radical (and
thence other kinds of ROS) that can react with proteins and lipids to
denature them, leading to insoluble plaques and other ﬁbrotic
structures that can themselves bind/entrap the iron that caused their
formation. This bound iron can cause further hydroxyl radical
formation such that the process is autocatalytic. Eventually this
overwhelms cellular defences, leading to cell death (with further
release of iron)
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123been observed, for instance, for Alzheimer’s (e.g. Colling-
wood et al. 2008; Connor et al. 1992; El Tannir El
Tayara et al. 2006; Ghribi et al. 2006; Haacke et al. 2005;
Lovell et al. 1998; Morgan et al. 2004; Quintana 2007;
Quintana et al. 2006; Sayre et al. 2000b; Schrag et al.
2009), ALS (Leveugle et al. 1997), MS (Haacke et al.
2009) and Parkinson’s (see above).
Sepsis, septic shock and the systemic inﬂammatory
response syndrome
Although prions lack nucleic acids, they are seen as
infectious agents. Bacteria are more conventional infective
agents, and bacterial sepsis provides a very interesting
example in which iron release is the key to cell death and
the multiple organ failure that normally precedes organis-
mal death. This said, the processes leading to septic shock
and ultimately death (Fig. 8) are independent of the pres-
ence of viable/culturable bacteria (as deﬁned in Kaprely-
ants et al. 1993; Kell et al. 1998), i.e. in the apparent
absence of infection (Goris 1990; Suntharalingam et al.
2006). This is because it is the products of bacteria,
especially lipopolysaccharide (LPS), that cause the cells
themselves to initiate the progressive processes of self-
destruction. The sequelae are typically referred to as a
systemic inﬂammatory response syndrome (SIRS) (e.g.
Baue et al. 1998; Beal and Cerra 1994; Bolton 1996; Bone
1996; Davies and Hagen 1997; Gutteridge and Mitchell
1999; Hotchkiss and Karl 2003; Johnson and Mayers 2001;
Keel and Trentz 2005; Leithead et al. 2009; Lolis and
Bucala 2003; Martin et al. 2003; Nguyen et al. 2006; Protti
and Singer 2006; Rittirsch et al. 2008; Ulloa et al. 2009).
It is by now well established that—while a ‘cytokine
storm’ (Huang et al. 2005; Sriskandan and Altmann 2008;
Stacey et al. 2009; Suntharalingam et al. 2006; Wang and
Ma 2008; Woo et al. 2010) is an important part of the
aetiology of sepsis/septic shock—these phenomena are
associated with the hyperproduction of ROSs (Abdelrah-
man et al. 2005; Andrades et al. 2005; Bulger and Maier
2001; Cadenas and Cadenas 2002; Closa and Folch-Puy
2004; Crimi et al. 2006a, b; Goode and Webster 1993;
Gutteridge and Mitchell 1999; Horn 1998; Javadi et al.
2005; Lagan et al. 2008; Lemineur et al. 2006; Mishra
2007; Protti and Singer 2006; Quinlan et al. 2001; Redl
et al. 1993; Victor et al. 2004, 2005; Vlessis et al. 1995),
and (local and circulating) free iron is raised in sepsis and
related conditions (Duvigneau et al. 2008; Galley et al.
1996, 1997; Galley and Webster 1996; Ghio et al. 2003;
Lagan et al. 2008), as is the iron siderophore-binding
protein lipocalin-2 (Hattori et al. 2009).
The natural iron-chelating antioxidant melatonin has
been found to be particularly effective in preventing septic
shock (Carrillo-Vico et al. 2005; Escames et al. 2006;
Reynolds et al. 2003), and a variety of suitable antioxidants
have shown promise (Bekyarova et al. 2009; Cuzzocrea
et al. 2001, 2004; Di Paola et al. 2006; Galley et al. 1997;
Mishra 2007; Nathens et al. 2002; Sebai et al. 2009; Streck
et al. 2008; Zapelini et al. 2008). Most importantly, anti-
oxidants are especially effective when given in combina-
tion with iron chelators (Barichello et al. 2007; Ritter et al.
2004, 2006) (see also Bulucu et al. 2009; Cassol et al.
2009; Petronilho et al. 2009; Pinho et al. 2005; Teixeira
et al. 2008; Valvassori et al. 2008). Erythropoietin is also
protective (Abdelrahman et al. 2004; Cuzzocrea et al.
2006), as is the iron-binder lactoferrin (Tian et al. 2010)
and as are anti-inﬂammatory statins (Durant et al. 2004;
Gao et al. 2008; Kopterides and Falagas 2009). All of these
observations make it very clear indeed that iron is inti-
mately involved in the death following SIRS and sepsis,
and—while not even mentioned in the guidelines (Dellinger
et al. 2008)—that its effective chelation should be consi-
dered for research leading towards its inclusion as an
important part of any therapy.
Bactericidal antibiotics
The classical test for if a bacterium is (or was) ‘alive’ is to
analyze its ability to multiply, i.e. viability = culturability
(Kell et al. 1998; Postgate 1967, 1976). Accordingly,
bacterial antibiotics have long been classiﬁed into those
that are bacteriostatic, i.e. stop individual cells growing but
allow culturability to recover if the antibiotic is removed,
and those that are bactericidal, i.e. that actually kill cells
and thereby decrease the numbers of those that are
Some events in sepsis/SIRS
LPS and/or other bacterial components
Release from endothelium and monocytes of 
pro-inflammatory cytokines, RNSs, ROSs
Release of poorly liganded iron 
and further OH￿formation
Sepsis and multiple organ failure
+
Organismal death
Fig. 8 The major events accompanying sepsis and the Systemic
Inﬂammatory Response Syndrome. Note in particular the positive
feedback by which the release of pro-inﬂammatory cytokines and
ROSs leads to the release of poorly liganded iron (e.g. from ferritin
and haem) that causes the release of further inﬂammatory cytokines
and ROSs. In principle, iron chelators could interfere with this vicious
cycle
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is removed. Since this clearly implies that causing growth
to cease is not of itself bactericidal, and anyway different
antibiotics have a variety of different modes of action, it
has always been a slight mystery as to what it is that makes
a particular antibiotic bactericidal rather than merely
bacteriostatic.
A very important paper (Kohanski et al. 2007) provides
much of the answer. As one may suppose from the subject
matter of this review, iron is again involved, speciﬁcally
via the Fenton reaction in which poorly liganded ferrous
ions reduce the comparatively harmless hydrogen peroxide
to the deadly hydroxyl radical.
Based on a previous paper from the same group (Dwyer
et al. 2007), Kohanski et al. (2007) (see also Davies et al.
2009; Dwyer et al. 2007, 2009; Imlay 2008; Kohanski et al.
2008; Liu et al.2009a; Wang and Zhao, 2009) reported that
the three major classes of bactericidal antibiotics (exem-
pliﬁed by norﬂoxacin, ampicillin and kanamycin), regard-
less of drug–target interaction, utilize internal iron
liberated from iron–sulphur clusters to promote Fenton-
mediated hydroxyl radical formation in bacteria, that such
hydroxyl radical generation contributes to the killing efﬁ-
ciency of these lethal drugs (probably via their known
ability to damage DNA), and that in contrast antibiotics
that are merely bacteriostatic do not cause the production
of such hydroxyl radicals. The availability of multiple
genetically marked strains allowed several predictions
(such as the resistance to be expected in mutants that could
not make iron-sulphur centres so effectively) to be tested
successfully. Nitric oxide is correspondingly protective
(Gusarov et al. 2009). This suggests, much as above, that
there is a common mechanism of iron/hydroxyl-mediated
cellular death underlying the action of all classes of bac-
tericidal antibiotics and opens up many new possibilities
for combination therapies based on promoting this kind of
activity selectively (see Fig. 9). This said, how synergistic
a combination is does depend on the exact speciation of the
liganded iron; surprisingly, the iron chelator deferasirox
promoted the antibacterial activity of ciproﬂoxacin against
V. vulniﬁcus (Neupane and Kim 2010), as did deferiprone
with various azoles against Aspergillus fumigatus, while
deferoxamine was antagonistic to azoles (Zarember et al.
2009). As with any complex system, the interactions can be
highly dosedependent (Hegreness et al. 2008; Kohanski
et al. 2010; Yeh et al. 2009).
Viruses
A typical viral infection involves the biding of virus to the
cell surface followed by internalisation and other effects.
Some viruses are especially virulent, and as well as
inﬂammation cause the death of cells that they have
invaded. It is obviously of interest to establish whether iron
is involved in this kind of cell death (and if so whether iron
chelation might contribute to a suitable therapy during the
acute phase of an infection).
The above suggestions are certainly true of infections
caused by inﬂuenza A (Visseren et al. 2002) (see also
Akaike et al. 1996; Beck et al. 2004), herpes simplex virus
(Gennero et al. 2010; Lamey and Biagioni 1995; Romeo
et al. 2001), hepatitis C (Alavian and Tabatabaei 2009;
Alla and Bonkovsky 2005; Ameli et al. 2008; Bassett 2007;
Batts 2007; Bonkovsky 2002; Bonkovsky et al. 2006;
Desai et al. 2008; Di Marco et al. 2008; Drakesmith and
Prentice 2008; Fargion et al. 2002; Ferrara et al. 2009;
Franchini et al. 2008; Fujita et al. 2007a, b; Fujita and
Takei 2007; Girelli et al. 2009;G u ¨rkan et al. 2005;
Guyader et al. 2007; Hayashi and Yano 2002; Heathcote
2004; Kaito 2007; Kaito et al. 2006; Kato et al. 2001, 2007;
Ko et al. 2007; Mahmoud et al. 2008; Mueller et al. 2006;
Nahon et al. 2008; Nishina et al. 2008; Otogawa et al.
2008; Price and Kowdley 2009; Rigamonti et al. 2005;
Sebastiani and Walker 2007; Sikorska et al. 2010;
Sugimoto et al. 2009; Tanaka et al. 2007; Tanaka and
Kiyosawa 2004; Trinder et al. 2008; Tung et al. 2003;
Valenti et al. 2008; Venturini et al. 2010; Won et al. 2009)
and HIV (Boelaert et al. 1996; Butensky James et al. 2009;
de Monye ´ et al. 1999; Debebe et al. 2007; Drakesmith and
Prentice 2008; Georgiou et al. 2000; Gordeuk et al. 2001,
2006; Kagu et al. 2007; Ketonen et al. 1996; McDermid
et al. 2007; McDermid and Prentice 2006; McDermid et al.
Stimulation of respiratory chain
Superoxide production
Damage to Fe-S cluster
Fe2+ liberated
Hydroxyl radical formation
CELLULAR DAMAGE AND
APOPTOTIC DEATH
Peroxide production
Fenton
Fe3+
Haber-Weiss
Fig. 9 A diagram, based very loosely on the narrative in (Kohanski
et al. 2007), illustrating how the autocatalytic activity of the reactions
of superoxide, peroxide and the hydroxyl radical involving poorly
liganded iron can exert a positive feedback leading to the death of
cells
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1232009; Meyer 2006; Northrop-Clewes 2008; Rawat et al.
2008; Savarino et al. 1999; Schreck et al. 1992; Szajerka
and Jablecki 2007; Traore ´ and Meyer 2004, 2007; van
Asbeck et al. 2001; Weinberg 2006; Ziegler et al. 2001).
Microbial, plant and animal toxins
Before considering chemical toxicants, it is worth noting
that the natural world contains a very great many molecules
that are toxic to cells and hence organisms. Although the
mechanisms of cell death are rather rarely pursued, there is
evidence for the involvement of iron in the sequelae of
exposure to toxic doses of gentamicin (Petronilho et al.
2009), ochratoxin (Hasinoff et al. 1990; Omar et al. 1990;
Størmer and Hoiby 1996) and ricin (Hassoun and Wang
1999; Kumar et al. 2003; Muldoon et al. 1996), as well as
to certain snake venoms (Gutierrez et al. 2010).
Chemical toxicants: aniline, asbestos, dioxins,
hydrazines, methyl mercury and paraquat
The most dangerous kinds of man-made toxic chemical
agents, those that kill cells or organisms, exhibit a rich
diversity of chemical structures and can bind to multiple
cellular targets, to the extent that a unitary mode of action is
not considered likely. (This said, the same was thought to be
true for the mode of action of general anaesthetics or nar-
cotics, and they turn out to have a comparatively small
number of rather speciﬁc protein targets (Dobson et al.
2009; Dobson and Kell 2008; Franks 2006, 2008; Grasshoff
et al. 2006)). However, this does not mean that multiple
initial events do not at some point converge to a compara-
tively small number of crucial events of cell death (whether
through necrosis or apoptosis, Vanden Berghe et al. 2009),
equivalent to the ‘bow-tie’ model of cellular networks (see
e.g. Csete and Doyle 2004; Ma’ayan 2009; Ma et al. 2004,
2007; Ma and Zeng 2003; Oda and Kitano 2006; Rodrı ´guez-
Caso et al. 2009; Wang and Chen 2010; Zhao et al. 2006,
2010) and (Fig. 10), and my purpose here is to highlight the
evidence that iron-based mechanisms, largely based on
Fenton chemistry, are involved in a number of these cases.
A recent special issue on toxicants and neurodegeneration is
also of interest here (Gupta and Milatovic 2009).
Acetaminophen
Acetaminophen (paracetamol in the United Kingdom)
(ChEBI 46195) is a well-known analgesic that is never-
theless highly toxic at concentrations in excess of the
therapeutic dose, as it is converted to the electrophilic
N-acetyl-p-benzoquinone imine (NAPQI). If glutathione is in
insufﬁcient supply, the NAPQI cannot be conjugated
harmlessly by glutathione and so it reacts covalently with
proteins, especially mitochondrial proteins (Hinson et al.
2004; Jaeschke and Bajt 2006; Kon et al. 2004; Masubuchi
et al. 2005; Reid et al. 2005), resulting in apoptotic cell
death and organismal death via liver damage (e.g. Barker
et al. 1977; Beckett et al. 1989; James et al. 2003; Martin-
Murphy et al. 2010; Olaleye and Rocha 2008). One of the
effects of mitochondrial damage is iron release, and it has
long been known that iron chelators help prevent this
toxicity (Sakaida et al. 1995; Schnellmann et al. 1999).
Appropriate hydroxyl radical scavengers are also partly
protective (Chandrasekaran et al. 2009), while lactoferrin is
also protective, although not apparently only via its iron-
binding capacity (Yin et al. 2010).
Aniline
As is well known, the adulteration with aniline of cooking
oil in Spain showed that aniline so administered can be
exceedingly toxic to humans (the ‘toxic oil syndrome’, Hill
et al. 1987;V a ´zquez Roncero et al. 1983), especially in the
lungs and spleen. It is now clear (Bomhard and Herbold
2005; Khan et al. 1995, 1999; Ma et al. 2008; Mellert et al.
2004; Wang et al. 2005, 2008, 2010) that iron is heavily
involved in this via Fenton chemistry.
Asbestos
Many mutagens are carcinogens, typically by intercalating
into DNA, so it was not a priori obvious why asbestos
ﬁbres—enormously larger than the diameter of DNA—should
‘Bow-tie’ models of cellular networks
Many possible 
Input events
A small number of
intermediate effects
e.g. in iron metabolism
Many further 
sequelae
Ultimate
events e.g.
cell death
Fig. 10 ‘Bow-tie’ models of cellular networks. There are many
examples of cellular networks in which a large variety of possible
initial events leads to complex sequelae, but these are mediated via a
comparatively small number of ‘intermediate’ reactions. While in the
present case it is suggested that these in part involve complex positive
feedbacks, the general ‘bow-tie’ idea does allow one to recognise that
despite the many different possible inputs, a broadly unitary kind of
mechanism of action—here involving iron dysregulation—can rea-
sonably be invoked to explain the multiple causes that can lead to cell
death and destruction
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123be so toxic. The mystery was solved when it was realised
that asbestos does in fact contain and bind iron, that the
sharp surface of the iron-loaded ﬁbres can catalyse
hydroxyl radical formation and that it is this that provides
the toxic mechanism (Aljandali et al. 2001; Burrows and
Muller 1998; Chao et al. 1996; Chen et al. 1996; Dai and
Churg 2001; Fubini and Arean 1999; Gilmour et al. 1997;
Governa et al. 1999; Gulumian and van Wyk 1987; Hardy
and Aust 1995a, b; Hippeli and Elstner 1999; Jaurand
1997; Kamp et al. 1992; Kamp and Weitzman 1997, 1999;
Kelleher et al. 2000; Levresse et al. 2000; Lund and Aust
1991, 1992; Mossman and Churg 1998; Mossman et al.
1987; Park and Aust 1998; Quinlan et al. 1994; Shatos
et al. 1987; Shen et al. 1995; Weinberg 1989; Weitzman
and Graceffa 1984; Xu et al. 1999; Azad et al. 2008;
Bhattacharya et al. 2005; Daghino et al. 2006; Fantauzzi
et al. 2010; Fattman et al. 2006; Gazzano et al. 2007;
Ghio et al. 2004, 2009; Heintz et al. 2010; Kamp 2009;
Knaapen et al. 2004; Liu et al. 2010; Nymark et al. 2008;
Panduri et al. 2006; Poser et al. 2004; Quinlan et al. 2002;
Shannahan et al.; Shukla et al. 2003a, b; Sørensen et al.
2007; Toyokuni 2009a, b; Upadhyay and Kamp 2003;
Valavanidis et al. 2009).
Dioxins
Dioxins are formed typically via the thermal combustion of
halogen-containing compounds, and a chief product,
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD, often referred
to simply as ‘dioxin’ (ChEBI 28119), notoriously produced
during the 1976 Seveso chemical plant explosion and as an
impurity in Agent Orange (a roughly 1:1 mixture of the
plant hormone (auxin—ChEBI 22676) analogues)
2,4-dichlorophenoxyacetic acid (2,4-D; ChEBI 28854) and
2,4,5-trichlorophenoxyacetic acid (2,4,5-T; ChEBI 27903),
is both a cause of chloracne and is a hepato-carcinogen. It
was found that mice low in iron are resistant to this hep-
atotoxicity however (Poland and Knutson 1982; Sweeny
et al. 1979), strongly implicating iron. In addition, iron
enhances the toxicity of dioxin (Al-Turk et al. 1988; Smith
et al. 1998) while iron chelators reduce it (Al-Bayati and
Stohs 1987; Wahba et al. 1990). While the exact details
have still not been worked out, there is little doubt that iron
is important in the toxicity of a wide variety of polyhalo-
genated aromatics (Smith and Chernova 2009; Smith and
Elder 2010), including hexachlorobenzene (ChEBI 5692)
(Franklin et al. 2005).
Hydrazines
Phenylhydrazine (ChEBI 27924) (like other hydrazines) is
a reactive substance that is commonly used in toxicity
studies. It is known (Agrawal et al. 2001; Atanasova et al.
2004; Ferrali et al. 1997a, b; Fraenkel et al. 2009;
Karbownik et al. 2000; Kim et al. 2009; Latunde-Dada
et al. 2004; Rokushima et al.2007a, b; Sharma and Haldar
2009; Yamamoto and Kawanishi 1992) to induce haemo-
lytic anaemia and iron release and thence cytotoxicity.
Melatonin can be protective (Sharma and Haldar 2009).
Methyl mercury
Originally highlighted via ‘Minamata disease’ (a promi-
nent symptom of which, as with many neurological
disease, is ataxia), methylmercury (ChEBI 30785)i sa
well-known neurotoxicant (Clarkson et al. 2003). Like
most if not all other xenobiotics (Dobson et al. 2009a;
Dobson and Kell 2008; Dobson et al. 2009b; Kell and
Dobson 2009), it requires one or more carriers for cellular
uptake—in this case, when complexed to L-cysteine, the
‘large amino acid’ transporter (Kanai and Endou 2003;
Simmons-Willis et al. 2002; Yin et al. 2008). There is
certainly evidence that exposure to this agent causes oxi-
dative stress (Ali et al. 1992; Aschner et al. 2007; Atchison
and Hare 1994; Franco et al. 2009; Johansson et al. 2007;
Sanfeliu et al. 2003; Saraﬁan et al. 1994; Yee and Choi
1994, 1996; Yin et al. 2007) and raises cellular iron levels
(Ilba ¨ck et al. 2000) and that anti-oxidants (Dare ´ et al. 2000;
Kaur et al. 2006; Saraﬁan and Verity 1991; Shanker and
Aschner 2003; Usuki et al. 2001; Watanabe et al. 2009;
Yamashita et al. 2004; Zurich and Monnet-Tschudi 2009),
metallothioneins (West et al. 2008) and/or iron chelators
(Castoldi et al. 2001; LeBel et al. 1992; Saraﬁan and Verity
1991; Stohs and Bagchi 1995) can be protective. Taken
together, this does imply strongly a role for iron-mediated
cytotoxicity of the type highlighted herein in the patho-
genesis of methylmercury poisoning.
Paraquat
Paraquat (N,N0-dimethyl-4,40-bipyridinium dichloride;
ChEBI 34905) is a well-known herbicide and toxicant,
whose mode of action relies on the generation of super-
oxide radicals. As such, its toxicity may be expected to
be exacerbated by iron, and this is the case (Andersen
2003; Ayaki et al. 2005; Fernandez et al. 2000; Peng
et al. 2007, 2009). In addition, again as expected from
the above (and consistent with its structural similarity to
the Parkinson-inducing agent MPTP-1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine, ChEBI 17963), it can induce
Parkinson-like symptoms (Kaur et al. 2009; Miller et al.
2009; Ossowska et al. 2006; Peng et al. 2007, 2009). The
protection by molecules—such as ferritin (Kaur et al.
2009) and polyphenols (Jimenez-Del-Rio et al. 2010)—
capable of chelating iron harmlessly is thus of consider-
able interest.
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123Other toxicants in which iron release has been
implicated as part of the mechanisms of their toxicity
Thelistofknownandpotentialtoxicantsislimitless,andpart
of the role of this review is to alert domain experts to the
likelihood that iron, and dysregulation in iron metabolism,
may mediate the toxicityof such molecules (and thus that its
chelation may be important, under both acute and chronic
conditions, in assisting resolution of the toxicity). To this
end, I note the role of iron-induced oxidative stress in the
toxicity of anthracyclines (including adriamycin/doxorubicin
ChEBI 28748) (Ceyssens et al. 2004; Kaiserova ´ et al. 2007;
Kotamraju et al. 2002, 2004; Luft 2006; Othman et al. 2008;
S ˇimu ˚nek et al. 2009; Thougaard et al. 2010; Xu et al. 2008),
arsenic (De Vizcaya-Ruiz et al. 2009; Fujihara et al. 2009),
beer brewed in cast iron pots (Kew and Asare 2007),
bleomycin(ChEBI 3139)(Wu etal.2004;Yangetal.2010),
C60 fullerenes (Usenko et al. 2008), carbon nanotubes
(Murrayetal.2009)(andseeGuoetal.2007;Jurkschatetal.
2007), carbon tetrachloride (Mansour 2000; Ogeturk et al.
2004),organophosphates(Goeletal.2006),sulphurmustard
agents (Korkmaz et al. 2008; Korkmaz et al. 2006; Naghii
2002) and talc nanoparticles (Akhtar et al. 2010). Welding
fumes are toxic and contain bothiron and manganese(Flynn
and Susi 2010; Sriram et al. 2010), and the toxicity of nano-
iron itself has also been studied (Li et al. 2009).
Apoptosis or necrosis?
As is well known, cells can die by both necrosis and by a
more regulated form, apoptosis. While this—nor ‘normal’
ageing (summarised e.g. by Bishop et al. 2010b; Finkel
2005; Franco et al. 2007; Gems 2009; Kenyon 2010;
Kirkwood 2008; Muller et al. 2007; Vaupel 2010), in which
various degradative processes including iron dysregulation
can be implicated (e.g. Brewer 2010; Cass et al. 2007; Cook
and Yu 1998; Facchini 2002; Galaris et al. 2008; Kell
2009a; Kujoth et al. 2005; Kurz et al. 2008b; Massie et al.
1983; Napoli et al. 2006; Pfefferbaum et al. 2009; Terman
et al. 2010; Xu et al. 2010)—is not the focus of this review,
it is reasonable to enquire as to what kind of evidence exists
for the mechanism(s) of cell death contingent upon iron
dysregulation. As it turns out, while there is a little evidence
that iron overload can cause necrosis (Babatasi et al. 1996;
Traore ´ and Meyer 2007; Vanden Berghe et al. 2009;
Vanlangenakker et al. 2008), there is abundant evidence for
the ability of iron to cause apoptosis (Kotamraju et al.
2004a, b; Kurz et al. 2007, 2008b; Vanden Berghe et al.
2009), and—depending presumably on the exact liganding
of the iron (Kell 2009a)—this can be effected when iron is
ostensibly depleted (e.g. Bergman et al. 2005; Bidle and
Bender 2008; Brard et al. 2006; Buss et al. 2003; Fukuchi
et al. 1994; Greene et al. 2002; Haq et al. 1995; Hileti et al.
1995; Jiang et al. 2002; Jin et al. 2007; Koc et al. 2006;
Kova ´r ˇ et al. 1997, 2001; Leardi et al. 1998; Lee et al. 2006b,
c; Pan et al. 2004; Simonart et al. 2000; Sun et al. 2009;
Truksa et al. 2003; Zhang et al. 2003; Zhao et al. 2004)o ri n
excess (e.g. Aljandali et al. 2001; Cozzi et al. 2003, 2010;
Devireddy et al. 2005; Franke et al. 2010; Jacob et al. 1997,
2000; Javadi et al. 2004;J ı ´menez Del Rı ´o and Ve ´lez-Pardo
2004; Kamp et al. 2002; Kawabata et al. 1997; Kermer
et al. 2004; Kooncumchoo et al. 2006; Kruman et al. 1997;
Kummer et al. 2008; Kurz et al. 2007, 2008b; Lakshmi Devi
and Anuradha 2009; Lee et al. 2006d; Levenson 2005;L u
et al. 2008; Ma et al. 2009; Messer et al. 2009; Murakami
et al. 2006; Natoli et al. 2009; Persson 2005; Polla et al.
2003; Schlawe et al. 2004; Shin and Kim 2009; Shukla et al.
2003; Tenopoulou et al. 2005; Upadhyay and Kamp 2003;
Ve ´lez-Pardo et al. 1997; Zhao et al. 1997).
Inﬂammation and NF-jB
As reviewed in the previous survey (Kell 2009a) and else-
where (e.g. Shoelson and Goldﬁne 2009; Shoelson et al.
2007), inﬂammation lies at the heart of many of these pro-
cesses, and pathways involving NF-jB (see e.g.
http://www.nf-kb.org/) are especially core here (e.g. Ali and
Mann 2004; Circu and Aw 2010; Granic et al. 2009; Karin
2008; Karin and Greten 2005; Li et al. 2005; Maeda and
Omata2008;SimmondsandFoxwell2008;ZhangandRigas
2006). Of particular relevance in ROS/iron metabolism are
the facts that NF-jB is redox-sensitive (e.g. Aggarwal and
Sung 2009; Baeuerle and Henkel 1994; Chandrasekaran and
Taylor2008;Cho etal.1998; Dro ¨ge 2002; Fulda etal.2010;
Galarisetal.2008;Gloireetal.2006;GloireandPiette2009;
Ha et al. 2010; Haddad et al. 2000; Hayashi et al. 1993;
Janssen-Heininger et al. 2008; Lagan et al. 2008; Lukosz
et al. 2010; Nishi et al. 2002; Phillips et al. 2010; Schreck
et al. 1991, 1992; Schreck and Baeuerle 1994; Sen and
Packer 1996; She et al. 2002; Surh et al. 2005; Surh and Na
2008; Thannickal and Fanburg 2000; Trachootham et al.
2008, 2009; Valko et al. 2007; Weinberg and Chandel 2009;
Wondrak 2009; Xiong et al. 2003) and that there are links
between NF-jB and NGAL/lcn2 (Bu et al. 2006; Cowland
etal. 2003, 2006,2008; Karlsen et al.2010) and/or hepcidin
(Sowetal.2009;Tacchinietal. 2008).Speciﬁcityislikelyto
come, in part, via the frequency encoding of NF-jB activity
(Ashall et al. 2009; Nelson et al. 2004).
Catalytic behaviour of polypeptides and proteins
I have mentioned several times the idea that different
proteins can bind unliganded iron to catalyse the
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123production of hydroxyl radical, and it is certainly the case
that the degree of liganding can affect these kinds of
activities (Kell 2009a). Here it is appropriate to highlight
the abilities of polypeptides and even poly(aminoacids)—
whether binding metals (or not)—to exhibit catalytic
activities, e.g. poly(leucine) (Carrea et al. 2005; Porter
et al. 1999), and how adding metals to polypeptides to
make metalloenzymes can have huge effects on their cat-
alytic activities (Pierron et al. 2008; Pordea and Ward
2008; Turner 2009). The recent development of orthogonal
ribosomes capable of incorporating novel amino acids into
polypeptides (Neumann et al. 2010) opens up considerable
possibilities here.
Dietary and/or pharmacological treatment of iron-
mediated toxicity
Pharmaceutical
Developing novel pharmaceutical agents is a costly enter-
prise, and many candidate drugs fall by the wayside during
the development process (see e.g. Dobson et al. 2009b;
Kola and Landis 2004; Leeson and Springthorpe 2007). As
most recently reviewed (Agarwal 2010; Berdoukas et al.
2009; Bolognin et al. 2009a; Cappellini and Pattoneri 2009;
Cappellini et al. 2010; Clifton et al. 2009; Hider et al. 2008;
Kell 2009a; Kontoghiorghes et al. 2010; Kwiatkowski
2010; Mlade ˘nka et al. 2009; Pennell et al. 2010; Perez and
Franz 2010; Richardson et al. 2009b and references
therein), a number of (pharmacological drug) approved
iron chelators do exist and thus clearly have the potential to
prove beneﬁcial in treating diseases and the sequelae of
toxin exposure whose aetiology involves poorly liganded
iron via the Fenton reaction. The beneﬁts of administration
of desferrioxamine in Alzheimer’s, for instance, have been
known for nearly 20 years (Crapper McLachlan et al.
1991), beneﬁts since observed with other iron chelators
(e.g. Amit et al. 2008; Bolognin et al. 2009a; Bush 2008;
Liu et al. 2009b, 2010b; Perez and Franz 2010; Smith et al.
2010; Zhang et al. 2009). The implications for this and
other neurodegenerative diseases—and potentially for the
more acute and even chronic effects of other toxins—are
obvious. Those approved clinically include Deferoxamine
(Desferal; ChEBI 31460), Deferiprone (Ferriprox; Pub-
Chem CID 2972) and Deferasirox (Exjade; ChEBI 49005)
(Fig. 11). Note that—unlike the other two—Deferoxamine is
not orallyactive and must be injected, and eventhen may fail
to cross cellular membranes to exert its action appropriately
(Warkentin et al. 2010).
Dietary or nutritional/nutraceutical
In addition, many organisms make so-called ‘secondary’ or
natural products, whose functions are often unclear but
Some clinically approved iron chelators
Deferiprone (Ferriprox; PubChemCID 2972)
Deferoxamine (Desferal; ChEBI 31460)
Deferasirox (Exjade; ChEBI: 49005)
Fig. 11 The three main iron
chelators approved for clinical
use
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(Hadaceketal.2010;Kelletal.1995).AsIalsoreviewed(Kell
2009a), many iron-chelating natural products exist in (or
may be added to, Po ´csi et al. 2008) foodstuffs for which no
full pharmaceutical regulatory controls are required and
which are classed as nutritional substances. Many are
polyphenols (ChEBI 26195) (Amic et al. 2007; Arts and
Hollman 2005; Auclair et al. 2009; Cemeli et al. 2009;
Cheynier 2005; Geronikaki and Gavalas 2006; Halliwell
2007; Jovanovic and Simic 2000; Kandaswami and
Middleton 1994; Kiokias et al. 2008; Korkina and
Afanas’ev 1997; Linseisen and Rohrmann 2008; Loke et al.
2009; Manach et al. 2004, 2005a, b;P e ´rez-Jime ´nez et al.
2010; Perron and Brumaghim 2009; Perron et al. 2008;
Petti and Scully 2009; Pietta 2000; Rice-Evans and Packer
2003; Scalbert et al. 2005; Scalbert and Williamson 2000;
Seifried et al. 2007; Slemmer et al. 2008; Spencer et al. 2008;
Yadav and Bhatnagar 2007a, b, 2010), including the
anthocyanins that proved chemoprotective (Butelli et al.
2008) in a mouse p53 cancer model. Since the previous
review (Kell 2009a), I would draw particular attention to a
comprehensive overview of the subject (Perron and
Brumaghim 2009), as well as new reviews and papers on
the chief polyphenol in green tea, (-)epigallocatechin-3-
gallate (ChEBI 4806) (Adhami et al. 2009; Butt and Sultan
2009; Hsieh et al. 2009; Jimenez-Del-Rio et al. 2010;
Johnson et al. 2010; Pandey and Gupta 2009; Paterniti et al.
2009; Ramesh et al. 2009; Reznichenko et al. 2010;
Suh et al. 2009; Weinreb et al. 2009a), on curcumin
(ChEBI 3962) (a constituent of turmeric) (Aggarwal and
Harikumar 2009; Aggarwal and Sung 2009; Anand et al.
2010; Basile et al. 2009; Epstein et al. 2009; Hegde et al.
2009; Iqbal et al. 2009; Jiao et al. 2009; Jurenka 2009;
Kalpravidh et al. 2010; Majumdar et al. 2009; Messner
et al. 2009; Patil et al. 2009; Ravindran et al. 2009; Rivera-
Espinoza and Muriel 2009; Thephinlap et al. 2009; Thomas
et al. 2009; Tuntipopipat et al. 2009; Wang et al. 2009a),
on eugenol (ChEBI 4917) (Nagababu et al. 2010) (and
cf. Allen and Cornforth 2009), on nepetoidin caffeic acid
esters (Maioli et al. 2010), on quercetin (ChEBI 16243)
(Chobot 2010; Kitagawa et al. 2009; Krukoski et al. 2009;
Lorrain et al. 2010; Park et al. 2010; Pavlica and Gebhardt
2010; Smirnova et al. 2009; Terao 2009; Vlachodimitro-
poulou et al. 2010) and on melatonin (CHEBI 16796)
(Borah and Mohanakumar 2009; Korkmaz et al. 2008,
2009; Reiter et al. 2009; Sener et al. 2009; Sharma and
Haldar 2009; Signorini et al. 2009). Many of the protective
effects observed are likely due to the iron chelating, as well
as directly antioxidative (redox) properties of these mole-
cules (e.g. Ferrali et al. 1997a; Hague et al. 2006; Halliwell
2009; Halliwell et al. 2005; Hider et al. 2001; Konc ˇic ´ et al.
2010; Lopes et al. 1999; Mandel et al. 2004; Mandel and
Youdim 2004; Morel et al. 1994; Nijveldt et al. 2001;
Rice-Evans et al. 1997; Rice-Evans and Packer 2003;
Weinreb et al. 2007, 2009a; Yoshino and Murakami 1998).
Other molecules that are not themselves directly antioxi-
dant, but have iron-binding characteristics, may also be
of beneﬁt. This is certainly true of phytic acid (phytate;
myo-inositol-1,2,3,4,5,6-hexakis phosphate; CHEBI 17401
) (Aljandali et al. 2001; Allen and Cornforth 2009; Brune
et al. 1989; Davidsson et al. 1994; Doria et al. 2009; Glahn
et al. 2002; Graf and Eaton 1990, 1993; Graf et al. 1987;
Grases et al. 2001; Hallberg et al. 1989; Han et al. 1994;
Hanson et al. 2006; Hawkins et al. 1993; Kamp et al.
1995a, b, 2002; Kim et al. 2008; Kumar et al. 2010;
Minihane and Rimbach 2002; Miyamoto et al. 2000;
Panduri et al. 2006; Poser et al. 2004; Rao et al. 1991;
Rimbach et al. 2008; Sandberg et al. 1999; Schlemmer
et al. 2009; Shamsuddin 1995; Vucenik and Shamsuddin
2006; Xu et al. 2008).
Phlebotomy
In addition, as follows implicitly from Sullivan’s ‘iron
hypothesis’ (Sullivan 1981, 2001, 2003, 2004) (and see
Kell 2009a), one way to decrease the amount of iron in the
body is to remove it by blood-letting or phlebotomy. While
phlebotomy is a very traditional nostrum, often assumed or
considered to have rather dubious or at best modest sci-
entiﬁc support, there is in fact increasing literature imply-
ing its beneﬁts in a variety of conditions (e.g. Aigner et al.
2008; Beutler 2007; Broedbaek et al. 2009; Brudevold
et al. 2008; Busca et al. 2010; DePalma et al. 2007, 2010;
Dereure et al. 2008; Desai et al. 2008; Dwyer et al. 2009;
Equitani et al. 2008; Facchini et al. 2002; Fargion et al.
2002; Ferna ´ndez-Real et al. 2002; Fujita et al. 2009; Fujita
and Takei 2007; Hayashi et al. 2006; Hayashi and Yano
2002; Heathcote 2004; Horwitz and Rosenthal 1999; Hua
et al. 2001; Kaito 2007; Kaito et al. 2006; Kato et al. 2001,
2007; Kom et al. 2006; Rajpathak et al. 2009; Sullivan
2009; Sumida et al. 2009; Tanaka et al. 2007, 2009;
Toyokuni 2009b; Zacharski et al. 2008). Plausibly such
beneﬁts are due to its role in decreasing iron stores.
Discussion: toxicology as systems biology
‘‘When sorrows come, they come not single spies but
in battalions.’’ (Shakespeare, Hamlet.)
It is certainly the case that reasons for the co-occurrence
of two or more observables are that one causes the other or
they have the same, separate cause. Since I have argued
strongly here for the essentiality of iron dysregulation in a
variety of syndromes (and have omitted many others, such
as non-alcoholic (Baptista-Gonzalez et al. 2008; Kirsch
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(Breitkopf et al. 2009; Lecube et al. 2009)), and indeed
cancers of various kinds (see Kell 2009a), the implication
is that iron dysregulation can manifest in multiple different
ways and that these might co-occur. There is considerable
and increasing evidence for that (see e.g. Adibhatla and
Hatcher 2010; Baker et al. 2009; Beeri et al. 2008; Cole
et al. 2007; Franco et al. 2009; Janson et al. 2004; Kell
2009a; Li and Ho ¨lscher 2007; Mascitelli et al. 2009;
Neumann et al. 2008; Pandolfo 2009; Roriz-Filho et al.
2009; Schnaider Beeri et al. 2004; Starley et al. 2010;
Utzschneider and Kowdley 2010; Verduzco and Nathan
2009; Xu et al. 2009), with the exact outcomes being
determined by different levels of expression (see for
instance http://www.proteinatlas.org/) of different proteins
in different tissues.
In a similar vein, it is not news (Attwood et al. 2009;
Evans 2008; Hull et al. 2008; Kostoff 2002) that the large
ﬂoods of literature have led to something of a ‘balkanisa-
tion’ of the literature into increasingly specialised seg-
ments, and that this makes it hard to seek to bring together
such disparate parts of the literature so as to draw out
general truths (Dobson and Kell 2008; Kell 2009a), via the
methods of inductive reasoning (Kell and Oliver 2004;
King et al. 2004, 2009). As previously discussed, it is well
established on theoretical grounds alone that the activity of
any step in a biochemical network can inﬂuence the con-
centration of any variable (such as—ﬂeetingly—the
amount of hydroxyl radicals produced). Thus, while it is
better to derive quantitative models (e.g. Coveney and
Fowler 2005; Csikasz-Na ´gy 2009; Kell 2006a, b; Kell and
Knowles 2006; Kell and Westerhoff 1986a, b; Milo et al.
2010; Mogilner et al. 2006; Noble 2002, 2006, 2010; Oates
et al. 2009; Phillips and Milo 2009; Tomlin and Axelrod
2007), at the very minimum one should be looking quali-
tatively at those factors that should be increased or
decreased in order to improve the organism’s ability to
resist oxidative stress (Fig. 12).
Indeed, it is the very act of doing this that leads one to
recognise these kinds of complex problems as problems of
systems or network biology (Alon 2006; Klipp et al. 2005;
Palsson 2006). What do I mean by this?
A systems biology view of toxicology: toxicology
as systems biology
In the present case, I have adduced evidence that a range of
distinct aetologies, which manifest as a variety of different
syndromes or diseases, converge at some point on an
autocatalytic series of reactions, involving imperfectly
liganded iron, in the production of the very damaging
hydroxyl radical, that by causing the destruction of
appropriate cellular structures and proteins liberates further
‘free’ iron and other reactive oxygen species, thereby
effecting positive feedback (also known as ‘vicious cycles’,
Lin and Beal 2006; Proctor and Gray 2010; Proctor et al.
2007) that leads to the production of yet further damage.
The implication of this is that to be more speciﬁc we need
suitable network models of the biological systems of
interest (Kell 2007), and of how toxicants of any kind can
interact with their components.
Of course in the steady state, the amount of a substance is
governed both by the processes that create it and those that
decompose it (Fig. 13), and individual effects of particular
substances can vary qualitatively depending on concentra-
tions, as in hormesis (e.g. Calabrese 2008a, b, c; Calabrese
and Baldwin 1997, 2001, 2003; Calabrese and Blain 2005,
2009; Cook and Calabrese 2006; Cox 2009; Gems and
Partridge 2008;G o ´mez-Pinilla 2008; Hadacek et al. 2010;
Hayes 2009; Hoffmann 2009; Mattson 2008a, b; Radak
et al. 2008; Rattan 2004, 2008; Rattan and Demirovic 2009;
Factors affecting pro-oxidant potential
and cell damage
GREATER PRO-
OXIDANT POTENTIAL
AND CELL DAMAGE
GREATER RESISTANCE
TO CELL DAMAGE
(SU)PEROXIDES/OH￿
PEROXIDASES
UNLIGANDED Fen+
PRO-OXIDANTS
CYTOKINES
INFLAMMATION
OBESITY
ANTIOXIDANTS
(e.g. VITAMINS C, E; 
GLUTATHIONE)
Fe CHELATORS
SOD/CATALASE
ANTI-INFLAMMATORIES
CALORIC RESTRICTION
Fig. 12 The extent of cell damage caused by the unliganded iron-
catalysed production of ROSs and RNSs is determined by many
factors, some of which promote and some of which act against it.
While the existence of hormesis (see text) means that the see-saw
illustrated here is an imperfect metaphor, the diagram serves to
illustrate the complexity of the problem and the need for a systems
biology approach to its solution
Steady-state concentrations
C A
E
D
create remove
remove B
remove
remove
Fig. 13 The steady-state concentrations of a molecule depend on the
rates of production and removal of the molecule in question. Both
lowering creation and increasing removal represents a particularly
effective strategy relative to doing just one of these alone. Thus if C is
the hydroxyl radical we can lower its concentration by decreasing A
and/or B and by increasing the rates of the reaction to D and E. The
latter (decrease of concentration of C) may sometimes better be
effected by increasing the activities of enzymes yet further
downstream
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analysis should be a systems analysis. The simple fact
that, for instance, iron chelators improve prospects in
Alzheimer’s implies that there is a background level of
natural repair (otherwise chelators would only slow the
neurodegeneration and not reverse it) and that is not nec-
essarily apparent from measuring only net effects. Hence,
the need for accurate systems biology models.
The very fact that multiple reactions typically lead to the
creation (and destruction) of a given metabolite (such as
the hydroxyl radical) means that to minimise its concen-
tration it is best to modify many reactions simultaneously.
This exceptionally important point from systems biology
should underpin any scientiﬁc and therapeutic programs.
Systems biology methods
Systems biology methods are typically classiﬁed into
‘forward’ and inverse’ (Fig. 14). For the purposes of this
discussion, I shall concentrate on metabolic networks (in
contrast to signalling networks they transfer both matter
and information, Kell 2004). Metabolic and other networks
are ‘graphs’ in that they consist of entities (‘nodes’, such as
metabolites) that interact with each other via ‘edges’
(enzymatic reactions). There may of course be other
interactions such those that do not involve substrates or
products but are mediated via molecules (effectors) that
modify the rates of reactions. The distinction between
forward and inverse models is based on whether one starts
with the parameters or variables of the system. In meta-
bolic networks, the parameters are typically the starting
concentrations of substances present and the kinetic con-
stants (Km, Ki, Vmax, etc.) of the enzymes. The variables are
typically the concentrations of metabolic intermediates,
and the metabolic ﬂuxes that change over time until a
steady state (if such exists) is attained. It is important to
note that only the parameters control the system. In for-
ward systems biology, we thus seek to create a model of the
network based on its parameters, and this is done in four
phases, the ﬁrst two of which are qualitative and the second
quantitative (Herrga ˚rd et al. 2008; Kell and Knowles 2006;
Thiele and Palsson 2010).
Forward modelling
The ﬁrst qualitative stage is one in which are listed all the
reactions that are known to occur in the system or organism
of interest; in the modern era, and especially for metabolic
networks, these reaction lists are often derived in part from
genomic annotations (Arakawa et al. 2006; Palsson 2006)
with curation based on literature (‘bibliomic’) data (Duarte
et al. 2007; Thiele and Palsson 2010). A second stage,
again qualitative, adds known effectors (e.g. those involved
in forming feedback loops), while the third and fourth
stages—essentially amounting to molecular enzymology—
include the known kinetic rate equations and the values of
their parameters. Armed with such information, it is then
possible to provide stochastic and ordinary differential
equation models of the entire metabolic network of inter-
est. In some cases, it is possible to make simplifying
assumptions that require minimal knowledge of the kinetic
parameters of the system and allow one to generate a time
series of the system variables (Smallbone et al. 2007). An
attractive feature of metabolism, for the purposes of
modelling, is that, in contrast to signalling pathways,
metabolism is subject to direct thermodynamic and (in
particular) stoichiometric constraints (Palsson 2006). These
constraints are extremely important in reducing the search
space for the values of the kinetic parameters of the model,
and indeed constrain signiﬁcantly the states that the system
can adopt (Kell 2004; Palsson 2006).
The modelling community has access to many tools,
which are interoperable because they can be exchanged
using community standards (Kell 2008) of which the most
popular (Klipp et al. 2007) is SBML, the Systems Biology
Markup Language (Hucka et al. 2003)( http://www.sbml.
org/). Models are best made, and made available, in SBML.
In addition, there is recognition that it is desirable to be
clear about the meaning (semantics) of the elements in the
model (Ananiadou et al. 2006; Attwood et al. 2009; Kell
and Mendes 2008), since SBML puts no constraints on the
names given to entities, and we have pioneered (Herrga ˚rd
et al. 2008; Pettifer et al. 2009) the use of semantic
annotation of all the entities, whether by reference to per-
sistent databases or via database-independent means (e.g.
the use of SMILES (Weininger 1988) and InChI (Coles
et al. 2005; Stein et al. 2003) strings for small molecules).
This is consistent with the MIRIAM proposals for
describing the contents of a model accurately (Le Nove `re
et al. 2005), and we have also used (Herrga ˚rd et al. 2008)
the Systems Biology Ontology (http://www.ebi.ac.uk/sbo/)
Forward and inverse methods 
in systems biology
Forward: start with the system’s parameters 
(including its topology, kinetic constants and the 
‘starting’ concentrations) and model the time 
evolution of its variables
Inverse: start with the time series of the system 
variables and seek to infer the topology and 
parameters of the system that could produce them
Fig. 14 The relationship between ‘forward’ and ‘inverse’ methods of
systems biology. The comparison of two ‘inverse’ systems (one a
control and one treated with a toxin) in terms of the estimation of
which parameters have changed most allows one to infer the sites or
modes of action of that toxin [In a related manner we also
discriminate forward and reverse genetics, including chemical
genetics (Kell 2006a, b)].
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especially pertinent and useful ontologies. Tools also exist
for creating such networks using CellDesigner (http://
www.celldesigner.org/) and SBMLMerge (Schulz et al.
2006) for merging submodels, including visualising them
(via the Systems Biology Graphical Notation (Le Nove `re
et al. 2009)( http://www.sbgn.org/) e.g. via Arcadia (Ville ´ger
et al. 2010)( http://www.sourceforge.net/projects/arcadiapath-
ways/). Armed with such networks, it is possible to analyse
their dynamics and other properties using tools/ modelling
environments such as COPASI (Hoops et al. 2006)
(http://www.copasi.org/) and to compare model and
experimental data, conveniently stored using SBRML
(Dada et al. 2010). Models and attendant metadata are best
stored directly in databases, such as that set down in the
B-Net database model (see Li et al. 2003; Mehrotra et al.
2010) as used in our yeast model (Herrga ˚rd et al. 2008)( http://
www.comp-sys-bio.org/yeastnet).
Interrogating the model
Sensitivity analysis
Armed with a model, there are a number of important
studies that are usefully performed. The ﬁrst is the study of
the contribution of individual steps to the control of the
variables of interest. This is the domain of local and global
sensitivity analysis (Saltelli et al. 2004, 2008), to which we
have made signiﬁcant contributions (e.g. Lu ¨dtke et al.
2008; Sahle et al. 2008; Yue et al. 2006, 2007, 2008).
Sensitivity analysis studies the quantitative contribution of
individual steps to the overall control of a process. The
‘local’ version has been popularised in biochemistry as
‘metabolic control analysis’ (e.g. Fell 1996; Heinrich and
Schuster 1996; Kell and Westerhoff 1986a), and, for
instance COPASI (Hoops et al. 2006) calculates the control
or sensitivity coefﬁcients directly from a model. The results
of these kinds of analyses are represented by a rank order
of the most important reactions or parameters, which pro-
vides an important starting point for the combinatorial
analysis of these complex networks. Formalisms such as
Metabolic Control Analysis also explain why the modula-
tion of individual steps singly rarely has much of an effect
on an overall pathway (see e.g. Pe ´rez et al. 2009a, b),
reviewed by Gems (Gems and Doonan 2009), for a typical
example.
Combinatorial analysis of parameter sensitivity
As indicated above, it is commonly the case in complex
biochemical networks that while changes in individual
parameters have little effect on the behaviour of bio-
chemical pathways—indeed evolution is thought to have
selected for robustness to individual parameter changes
(Bornholdt and Sneppen 2000; Kitano 2007; Leha ´r et al.
2008; Morohashi et al. 2002; Stelling et al. 2004; Wagner
2005)—combinations of parameter changes can and do
have major effects. A straightforward corollary of this is
that in order to cause or inhibit the progression of dis-
eases—including inﬂammatory diseases such as asthma
(Biswas and Rahman 2009; Bowler 2004; Bowler and
Crapo 2002; Boyer and Liu 2004; Chodaczek et al. 2007;
Ciencewicki et al. 2008; Comhair and Erzurum 2010; Galli
et al. 2008; Greene 1995; Han et al. 2001; Horva ´th et al.
1998; Jarvis et al. 2005; Kocyigit et al. 2004; Mun ˜oz et al.
2009; Narula et al. 2007; Nemery 1990; Pae et al. 2008;
Riedl and Nel 2008; Shore 2008; Vlas ˇic ´ et al. 2009)—it is
necessary to affect multiple steps simultaneously. The
problem is to ﬁnd which ones, and that is a combinatorial
problem that scales poorly. It is exactly here where the
ability to interrogate a suitable model of the pathway
comes to the fore, since computations to determine which
combinations of parameters to affect can be done enor-
mously more rapidly than can ‘wet’ experiments. To be
explicit, if manipulating (let us say knocking out) just three
genes out of 1,000 is necessary to secure a desired effect
(as is often the case) and the question is to choose which
three, the answer involves recognizing that this is a com-
binatorial optimization problem involving ca 100 million
combinations—a trivial number computationally given a
model and an easy number (i.e. 3) to work with post hoc,
but an implausible number to interrogate with present
experimental methods. See (Park et al. 2007, 2008) for a
nice example of the approach.
At all events, the results of running a systems biology
model in the forward direction are the time-varying con-
centrations of variables that result from the network
topology and parameters of the system, and these can then
be compared with measured variables to see how accurate
the model is.
Of course it is typically the case (i) that the variables
predicted by the model differ from those that one has
measured, and (ii) one has only measurements of the
variables and not the parameters anyway. Since it is the
parameters that determine the system behaviour, it is then
necessary to try and estimate or infer the parameters of the
systems from measurements of the variables, the domain of
inverse modelling (Liu and Wang 2008; Mendes and Kell
1996) or system identiﬁcation (Bongard and Lipson 2005;
Ljung 1987).
Inverse modelling
Finding the sets of parameters that can reﬂect a set (or sets)
of variables is a much harder problem. If there are just 20
parameters, each of which can take just 10 values, there are
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20 combinations, although there may be multiple
combinations that give a reasonable solution (the problem
or system is then said to be under-determined). At all
events, ﬁnding these combinations requires methods that
can effectively search these combinatorial search spaces to
ﬁnd good solutions (they are not provably optimal solutions
as these kinds of problems are NP-hard, Garey and Johnson
1979).
There are many kinds of approaches to attacking these
kinds of combinatorial optimisation problems, and I give
two examples. The ﬁrst uses evolutionary methods to
modify the search for these parameters, while the second is
Bayesian in character.
Evolutionary computing methods (e.g. Ba ¨ck et al. 1997;
Goldberg 1989, 2002) use ideas from Darwinian evolution
to select and modify parameters to achieve a desired
objective (or objectives—this is known as multi-objective
optimisation, Handl et al. 2007). In an evolutionary algo-
rithm, one selects a population of models encoding a dif-
ferent candidate set of parameters, assesses their
performance, rejects those that perform poorly and modi-
ﬁes the parameters of the better-performing models using
methods akin to recombination and mutation to create a
second generation population and so on. Finally, one ﬁnds
a candidate set of solutions that perform well and can
indeed interrogate these solutions to determine the
parameters that differ most frequently in the selected
solutions from those in the starting pathway. These kinds of
methods are recognised as highly effective (Banga 2008;
Banga and Balsa-Canto 2008), and they have proved so for
both modelling (Dada and Mendes 2009; Mendes and Kell
1998; Moles et al. 2003; Rodriguez-Fernandez et al. 2006)
and other optimisation problems (e.g. Broadhurst et al.
1997; Kell et al. 2001; Knight et al. 2009; O’Hagan et al.
2005, 2007; Platt et al. 2009; Rowe et al. 2010). A related
and novel approach that we have developed (Wilkinson
et al. 2008) (and see Brown et al. 2010) also evolves
estimates of parameters, but in a somewhat different way.
Evolutionary computing methods are amenable to (‘coarse-
grained’) parallelisation that allows them to run on many
(hundreds or even thousands of) processors simultaneously,
and we have used this approach with great effectiveness
(Wedge and Kell 2008; Wedge et al. 2009). Overall, the
result of this kind of approach is the effective determina-
tion of the multiple parameters that are required to explain
the system variables.
A conceptually quite different approach, which may of
course be expected to lead to the same result (and which in
consequence strengthens further any conclusions from e.g.
an evolutionary computing approach), is an approach based
on Bayesian inference (Jayawardhana et al. 2008; Lieber-
meister and Klipp 2006; Vyshemirsky and Girolami 2008)
and known as Markov Chain Monte Carlo or MCMC. In
this approach (which we do not rehearse in detail as those
details have recently been published by us, Jayawardhana
et al. 2008), we have knowledge of the variables of interest
and sample candidate models that can explain those vari-
ables using various estimates of their parameters from a
distribution. The MCMC algorithm then slowly builds up
the likeliest values of the parameters and their possible
distribution given the demonstrable uncertainty.
Detecting the modes or sites of action of a toxin
Clearly, if we have measurements of the variables of a
system before and after the addition of a toxin, we can
estimate the parameters in the two cases and see which
have most plausibly changed by applying these inferencing
methods to the two cases. This automatically gives the
mode(s) or site(s) of action of the intervention, whether of
a toxic inhibitor or by any other means. In other words
these methods can detect the modes or sites of action of
anything that causes a system to change its state. Taking
the Bayesian approach (see also e.g. Nidhi et al. 2006;
O’Hagan 2006; Vyshemirsky and Girolami 2008; Wilkinson
2007), in the work described above (Jayawardhana et al.
2008) we ‘calibrated’ our approach using purely simulated
data in which we knew exactly which parameters had
been changed (and in which direction) and showed that we
could detect this accurately. We then applied our approach
to an experimental system of metabolic engineering in
Lactococcus lactis (Hoefnagel et al. 2002) where the
investigators had manipulated the activity of a speciﬁc
enzyme to achieve a desired metabolic effect. Our
approach detected both the enzyme whose activity had
been modiﬁed and suggested the site of another signiﬁcant
pleiotropic effect (these always occur, Featherstone and
Broadie 2002). Thus, the power of this general approach is
that it is free of speciﬁc hypotheses and thus guides us to
the hypotheses that can best explain the data. These are
classic data mining methods (e.g. Breiman 2001; Kell and
King 2000; Kell and Oliver 2004; Wu et al. 2008) that
allow us to discover mechanisms of action that are
unknown and/or have not previously been contemplated.
Note, however, that such methods need careful handling
from a statistical point of view (e.g. Altman and Royston
2000; Broadhurst and Kell 2006; Hastie et al. 2001;
Ioannidis 2005, 2008). A variety of other network infer-
encing methods also exist (e.g. Lorenz et al. 2009;
Managbanag et al. 2008; Stolovitzky and Califano 2006;
Stolovitzky et al. 2009).
Why most toxins will have multiple sites of action
A variety of means are available for testing these mecha-
nisms further, including the use of modulation of the
846 Arch Toxicol (2010) 84:825–889
123expression of constituent parts of the proposed pathways by
genetic means (e.g. Jones et al. 2007), and in particular the
use of appropriate iron chelators and antioxidants, alone or
(preferably) in combination. The combinatorial aspect is
important, since there are theoretical grounds, as well as
abundant evidence, to the effect that several steps in a
network must be modulated simultaneously to exhibit
substantial effects (see e.g. A ´goston et al. 2005; Ambesi-
Impiombato and di Bernardo 2006; Bender et al. 2006;
Borisy et al. 2003; Csermely et al. 2005; Dancey and Chen
2006; Fan et al. 2003, 2006; Haggarty et al. 2003; Hopkins
et al. 2006; Kaelin 2005; Keith et al. 2005; Kostoff and
Delafuente 2006; Millan 2006; Perlstein et al. 2006;
Sharom et al. 2004; Shiomi et al. 1999; Wermuth 2004)
(Bro ¨tz-Oesterhelt and Brunner 2008; Chong and Sullivan
2007; Costanzo et al. 2010; Gerber et al. 2007; Goltsov
et al. 2009; Hegreness et al. 2008; Huang et al. 2008b; Jia
et al. 2009; Koufaki et al. 2009; Kuhn et al. 2010; Lee et al.
2007; Leha ´r et al. 2007, 2008a, b; Li et al. 2007; Liby et al.
2007; Morphy and Rankovic 2007; Pachauri et al. 2009;
Reznichenko et al. 2010; Sarkar and Li 2009; Sarkar et al.
2009; Sawyers 2007; Schrattenholz and S ˇos ˇkic ´ 2008;
Silver et al. 2009; Silver 2007; Sporn et al. 2007; Stommel
et al. 2007; Suchy et al. 2009; Ulrich-Merzenich et al.
2009; Watterson et al. 2008; Weinreb et al. 2009b;
Whitehurst et al. 2007; Wong et al. 2008; Yeh et al. 2006,
2009; Ying et al. 2008; Zamin et al. 2009; Zhang 2006;
Zhang et al. 2010; Zimmermann et al. 2007). The same
holds true for biotechnology (Kell and Westerhoff 1986a),
in which typically we seek to maximise ﬂuxes (Park et al.
2007, 2008). Of course some molecules—both nutrients/
natural products and pharmaceutical agents—can act as
both antioxidants and iron chelators; these are likely to be
especially useful in minimising the damage from toxicants
of many kinds.
Concluding remarks
Science consists of both analysis and synthesis, and thus a
substantial amount of Science involves ﬁnding regularities
(‘Laws’) that can be extracted from observables, even when
some of those observables or their presumed causes seem to
have little in common (Kell and Oliver 2004; Oldroyd 1986;
Westerhoff and Kell 2007). Thus, there are many kinds of
toxins that can cause death or injury, but it is not necessarily
obvious what they share in terms of their modes of action.
What I have therefore sought to do here is to bring together
the evidence for the autocatalytic involvement of poorly
liganded iron (leading, inter alia, to hydroxyl radical for-
mation) in a considerable number of these. Certainly the
exact molecular mechanisms, cascades and networks
involved in each case depend on many other factors, and
appropriate systems biology methods can tell us what they
are, but I would argue that the extensive evidence for iron’s
involvement that I cite here and elsewhere (Kell 2009a)i s
very hard to ignore. Hence, the view that iron is the nexus.
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